Electronic Supplementary Information

Palladium-Catalyzed Remote *para*-C–H Activation of Arenes Assisted by a Recyclable Pyridine-Based Template

Xiaoxi Chen, a,b Shuai Fan, a Meng Zhang, a Yuzhen Gao, a Shangda Li, a and Gang Li*. a,b

^aKey Laboratory of Coal to Ethylene Glycol and Its Related Technology, State Key Laboratory of Structural Chemistry, Center for Excellence in Molecular Synthesis, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian, 350002, China

^bFujian College, University of Chinese Academy of Sciences, Beijing, 100049, China

*E-mail: gangli@fjirsm.ac.cn

Table of Contents

1	Gene	S3	
2	Experimental Section		S4
	2.1	Synthesis of Different Scaffolds	S4
	2.2	Synthesis of Directing Template.	S13
	2.3	Synthesis of Substrates	S14
	2.4	Optimization of Reaction Conditions	S28
	2.5	General Procedures and Characterizations of Products	S36
	2.6	Scaled-up Reactions	S71
	2.7	Synthetic Applications and Hydrolysis	S71
3	NMF	R Spectrc of Compounds	S78
4	Refe	rences	

1 General Information

Unless otherwise noted, commercial available reagents were purchased from commercial suppliers (such as Strem, Alfa Aesar, J&K Chemical Co., Energy Chemical, Sinocompound and Adamas) and used as received. Solvents were generally dried over 4 Å molecular sieves. Hexafluoroisopropanol (HFIP) was dried over 4 Å molecular sieves and distilled before use. The reaction vessels used for C-H functionalization were 15 mL sealed tube or 50 mL Schlenk tube (Synthware). Purification of products was performed by flashchromatography (FC) using silica gel or preparative thin layer chromatography. ¹H and ¹³C NMR spectra were recorded on a Bruker AVANCE III spectrometer (400 MHz and 101 MHz, respectively). Chemical shifts are reported parts per million (ppm) referenced to CDCl₃ (δ 7.26 ppm) or DMSO-d₆ (δ 2.50 ppm), tetramethylsilane (TMS, δ 0.00 ppm) for ¹H NMR; CDCl₃ (δ 77.16 ppm) or DMSO-d₆ (δ 39.52 ppm) for ¹³C NMR. The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, hept = heptaplet, m = multiplet, and br = broad. To distinguish, some ${}^{13}C$ NMR chemical shifts retain two decimal places. High-resolution mass spectra (HRMS) were obtained on an Impact II UHR-TOF mass spectrometry equipped with an ESI source from Bruker at Fujian Institute of Research on the Structure of Matter.

2 Experimental Section

2.1 Synthesis of Different Scaffolds.

General Procedure I



To a solution of (3-bromophenyl)methanamine (3.0 mmol), hydrocinnamoyl chloride (3.6 mmol) and triethylamine (9.0 mmol) in DCM (10 mL) at room temperature stirred for 6 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-2:1) as the eluent to give *N*-(3-bromobenzyl)-3-phenylpropanamide.

To a dry round bottom flask under nitrogen atmosphere was charged with *N*-(3-bromobenzyl)-3-phenylpropanamide (3.0 mmol) and NaH (60% dispersion in mineral oil, 9.0 mmol). The bottom was placed into an ice bath for 10 minutes followed by addition of anhydrous THF (15 mL). After stirred for 0.5 h at 0 °C, MeI (4.5 mmol) was added dropwise to the mixture. The reaction was allowed to warm to room temperate and stirred for 12 h. H₂O was slowly added (be careful!!) to quench the reaction. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-3:1) as the eluent to give N-(3-bromobenzyl)-N-methyl-3-phenylpropanamide.

To a solution of *N*-(3-bromobenzyl)-*N*-methyl-3-phenylpropanamide (1.0 mmol), PdCl₂(PPh₃)₂ (0.01 mmol), pyridin-3-ylboronic acid (1.1 mmol) and K₂CO₃ (4.0 mmol) in 1,4-dioxane:H₂O = 4 mL: 1 mL under nitrogen atmosphere at 100 °C stirred for 12 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (3:1-2:1) as the eluent to give the desired compound.

General Procedure II



To a solution of (3-bromophenyl)methanamine (3.0 mmol), **a** (3.6 mmol) and triethylamine (9.0 mmol) in DCM (10 mL) at room temperature stirred for 6 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-2:1) as the eluent to give **b**.

To a solution of **b** (1.0 mmol), $PdCl_2(PPh_3)_2$ (0.01 mmol), (2-fluoropyridin-3yl)boronic acid (1.1 mmol) and K₂CO₃ (4.0 mmol) in 1,4-dioxane : H₂O = 4 mL : 1 mL under nitrogen atmosphere at 100 °C stirred for 12 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (3:1-2:1) as the eluent to give **c**.

To a dry round bottom flask under nitrogen atmosphere was charged with c (1.0 mmol) and NaH (60% dispersion in mineral oil, 3.0 mmol). The bottom was placed into an ice bath for 10 minutes followed by addition of anhydrous THF (5 mL). After stirred for 0.5 h at 0 °C, hydrocinnamoyl chloride (1.2 mmol) was added dropwise to the mixture. The reaction was allowed to warm to room temperate and stirred for 12 h. H₂O

was slowly added (be careful!!) to quench the reaction. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-3:1) as the eluent to give the desired compound.

N-methyl-3-phenyl-*N*-(3-(pyridin-3-yl)benzyl)propanamide (1a₁)

The general procedure I was followed. Yield: 231 mg, (70 %).Two rotamers can be observed on the NMR spectrum and the ratio is about 65:35.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.88 (s, 0.61H), 8.85 (s, 0.38H), 8.65 – 8.62 (m, 1H), 7.89 (d, *J* = 8.0 Hz, 0.65H), 7.85 (d, *J* = 7.6 Hz, 0.37H), 7.56 – 7.43 (m, 3H), 7.41 – 7.37 (m, 1H), 7.35 – 7.27 (m, 4H), 7.25 – 7.14 (m, 2H), 4.71 (s, 1.29H), 4.58 (s, 0.69H), 3.11 – 3.05 (m, 2H), 3.03 (s, 1.22H), 2.93 (s, 1. 91H), 2.75 (td, *J* = 7.8, 2.3 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.4, 172.2, 148.5, 148.3, 148.03, 148.00, 141.1, 141.0, 138.4, 138.3, 138.0, 137.5, 136.2, 136.0, 134.4, 134.3, 129.6, 129.2, 128.31, 128.29, 128.26, 127.6, 126.6, 126.3, 126.01, 125.98, 125.7, 124.8, 123.50, 123.46, 53.0, 50.7, 35.1, 34.8, 34.7, 33.9, 31.3, 31.1. HRMS (m/z, ESI-TOF): Calcd for C₂₂H₂₂N₂ONa⁺ [M+Na⁺] 353.1624, found 353.1625.



N-(3-(2-methoxypyridin-3-yl)benzyl)-*N*-methyl-3-phenylpropanamide (1a₂)

The general procedure I was followed. Yield: 180 mg, (50 %). Two rotamers can be observed on the NMR spectrum and the ratio is about 58:42.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.20 (td, J = 4.7, 1.9 Hz, 1H), 7.62 (dd, J = 7.3, 1.9 Hz, 0.62H), 7.58 (dd, J = 7.3, 1.9 Hz, 0.48H), 7.53 – 7.47 (m, 1H), 7.44 – 7.38 (m, 1.67H), 7.33 (s, 0.45H), 7.30 – 7.16 (m, 5.57H), 7.10 (d, J = 7.6 Hz, 0.43H), 6.99 (dd, J = 7.3, 5.0 Hz, 1H), 4.68 (s, 1.16H), 4.54 (s, 0.83H), 3.99 (s, 1.59H), 3.98 (s, 1.29H), 3.10 – 3.03 (m, 2H), 3.02 (s, 1.40H), 2.91 (s, 1.73H), 2.73 (q, J = 7.7 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.6, 172.2, 160.8, 160.7, 146.0, 145.8, 141.3, 141.2,

138.6, 138.5, 137.5, 137.3, 137.0, 136.5, 128.83, 128.80, 128.44, 128.41, 128.39, 128.37, 128.2, 127.2, 126.9, 126.10, 126.08, 125.3, 124.3, 124.0, 117.13, 117.12, 53.51, 53.49, 53.2, 50.8, 35.4, 34.9, 34.8, 34.1, 31.5, 31.3. HRMS (m/z, ESI-TOF): Calcd for $C_{23}H_{24}N_2O_2Na^+$ [M+Na⁺] 383.1730, found 383.1731.



N-(3-(2-fluoropyridin-3-yl)benzyl)-*N*-methyl-3-phenylpropanamide (1a₃)

The general procedure I was followed. Yield: 296 mg, (85 %). Two rotamers can be observed on the NMR spectrum and the ratio is about 65:35.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.25 – 8.17 (m, 1H), 7.89 – 7.79 (m, 1H), 7.52 – 7.40 (m, 3H), 7.31 – 7.24 (m, 5H), 7.22 – 7.12 (m, 2H), 4.67 (s, 1.37H), 4.55 (s, 0.73H), 3.08 – 3.01 (m, 2H), 3.00 (s, 1H), 2.92 (s, 2H), 2.72 (t, *J* = 7.8 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.7, 172.4, 160.41 (d, *J*_{*C*-*F*} = 240.1 Hz), 160.36 (d, *J*_{*C*-*F*} = 239.9 Hz), 146.7 (d, *J*_{*C*-*F*} = 14.6 Hz), 146.4 (d, *J*_{*C*-*F*} = 14.7 Hz), 141.33, 141.26, 140.8 (d, *J*_{*C*-*F*} = 4.4 Hz), 140.7 (d, *J*_{*C*-*F*} = 4.3 Hz), 138.1, 137.3, 134.7 (d, *J*_{*C*-*F*} = 4.8 Hz), 134.3 (d, *J*_{*C*-*F*} = 5.0 Hz), 129.4, 129.0, 128.51, 128.49, 128.4 (d, *J*_{*C*-*F*} = 2.9 Hz), 128.2, 128.1, 127. 9 (d, *J*_{*C*-*F*} = 3.0 Hz), 126.6 (d, *J*_{*C*-*F*} = 3.0 Hz), 126.3, 126.2, 123. 9, 123.6, 123.3, 121.98, 121.95, 121.9, 53.2, 50. 9, 35.4, 35.02, 34.96, 34.1, 31.5, 31.4. HRMS (m/z, ESI-TOF): Calcd for C₂₂H₂₁FN₂ONa⁺ [M+Na⁺] 371.1530, found 371.1531.



N-(3-(6-fluoropyridin-3-yl)benzyl)-*N*-methyl-3-phenylpropanamide (1a₄)

The general procedure **I** was followed. Two rotamers can be observed on the NMR spectrum and the ratio is about 66:34.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.30 (d, J = 2.6 Hz, 0.57H), 8.27 (d, J = 2.6 Hz, 0.35H), 7.82 (dtd, J = 19.6, 8.0, 2.6 Hz, 2H), 7.38 – 7.28 (m, 2.64H), 7.21 – 7.01 (m, 6.54H), 6.90 (dd, J = 8.5, 2.9 Hz, 1H), 4.57 (s, 1.31H), 4.45 (s, 0.65H), 2.97 – 2.91 (m, 2H), 2.90 (s, 1.10H), 2.81 (s, 1.87H), 2.62 (t, J = 7.8 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.6, 172.4, 163.3 (d, J_{C-F} = 239.6 Hz), 163.2 (d, J_{C-F} = 239.4 Hz),

145. 9 (d, $J_{C-F} = 14.7$ Hz), 141.3, 141.2, 139.9 (d, $J_{C-F} = 8.0$ Hz), 139.8 (d, $J_{C-F} = 7.9$ Hz), 138.6, 137.8, 137.5, 137.1, 134.6 (d, $J_{C-F} = 4.5$ Hz), 134.4 (d, $J_{C-F} = 4.5$ Hz), 129. 9, 129.4, 128.51, 128.48, 128.46, 127.8, 126.7, 126.4, 126.2, 126.1, 126.0, 124. 9, 109.6 (d, $J_{C-F} = 37.5$ Hz), 109.5 (d, $J_{C-F} = 37.5$ Hz), 53.2, 50.9, 35.3, 35.01, 34.98, 34.2, 31.5, 31.3. HRMS (m/z, ESI-TOF): Calcd for C₂₂H₂₁FN₂ONa⁺ [M+Na⁺] 371.1530, found 371.1531.



N-(3-(2-fluoropyridin-3-yl)benzyl)-3-phenyl-*N*-(phenylsulfonyl)propanamide (1as) The general procedure II was followed. Yield: 380 mg, (80 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.20 (d, *J* = 4.2 Hz, 1H), 7.79 (t, *J* = 8.2 Hz, 1H), 7.72 (d, *J* = 7.8 Hz, 2H), 7.60 (t, *J* = 7.4 Hz, 1H), 7.51 – 7.35 (m, 6H), 7.28 (d, *J* = 5.8 Hz, 1H), 7.18 – 7.10 (m, 3H), 6.99 (d, *J* = 7.0 Hz, 2H), 5.13 (s, 2H), 2.98 – 2.91 (m, 2H), 2.90 – 2.83 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.5, 160.4 (d, *J*_{*C*-*F*} = 240.6 Hz), 146.6 (d, *J*_{*C*-*F*} = 14.8 Hz), 140. 9 (d, *J*_{*C*-*F*} = 4.5 Hz), 140.2, 139.6, 137.3, 134.4 (d, *J*_{*C*-*F*} = 4.9 Hz), 133.9, 129.3, 129.2, 128.5, 128.4 (d, *J*_{*C*-*F*} = 3.4 Hz), 128.34, 128.27 (d, *J*_{*C*-*F*} = 2.5 Hz), 128.1, 127.7, 126.3, 123.6 (d, *J*_{*C*-*F*</sup> = 28.1 Hz), 122.0 (d, *J*_{*C*-*F*</sup> = 4.4 Hz), 49.3, 38.1, 30.7. HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₃FN₂O₃SNa⁺ [M+Na⁺] 497.1306, found 497.1306.}}



N-(3-(2-fluoropyridin-3-yl)benzyl)-3-phenyl-N-tosylpropanamide (1a₆)

The general procedure II was followed. Yield: 342 mg, (70 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.20 (dt, *J* = 4.9, 1.6 Hz, 1H), 7.82 – 7.77 (m, 1H), 7.60 (d, *J* = 8.4 Hz, 2H), 7.53 – 7.45 (m, 2H), 7.44 – 7.36 (m, 2H), 7.29 – 7.22 (m, 3H), 7.19 – 7.11 (m, 3H), 7.03 – 6.96 (m, 2H), 5.12 (s, 2H), 2.97 – 2.93 (m, 2H), 2.89 – 2.85 (m, 2H), 2.40 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.5, 160.4 (d, *J*_{C-F} = 240.1 Hz), 146.5 (d, *J*_{C-F} = 14.7 Hz), 145.1, 140.8 (d, *J*_{C-F} = 4.4 Hz), 140.2, 137.4, 136.6, 134.3 (d, *J*_{C-F} = 5.0 Hz), 129. 9, 129.1, 128.5, 128.32, 128.28, 128.2 (d, *J*_{C-F} = 2.4 Hz), 128.1, 127.7, 126.2, 123.6 (d, *J*_{C-F} = 28.2 Hz), 121.9 (d, *J*_{C-F} = 4.4 Hz), 49.3,

38.0, 30.7, 21.7. HRMS (m/z, ESI-TOF): Calcd for $C_{28}H_{25}FN_2O_3S$ Na⁺ [M+Na⁺] 511.1462, found 511.1463.



N-(3-(2-chloropyridin-3-yl)benzyl)-*N*-methyl-3-phenylpropanamide (1a₇)

The general procedure I was followed. Yield: 218 mg, (60 %). Two rotamers can be observed on the NMR spectrum and the ratio is about 64:36.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.32 (td, J = 5.1, 1.9 Hz, 1H), 7.58 (dd, J = 7.6, 2.0 Hz, 0.69H), 7.53 (dd, J = 7.5, 2.0 Hz, 0.42H), 7.33 (t, J = 7.8 Hz, 1H), 7.29 – 7.12 (m, 7H), 7.11 – 7.05 (m, 2H), 4.58 (s, 1.29H), 4.45 (s, 0.69H), 2.97 – 2.91 (m, 2H), 2.91 (s, 1.32H), 2.82 (s, 1. 92H), 2.62 (td, J = 7.8, 7.4, 2.5 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.7, 172.5, 149.70, 149.67, 148.7, 148.5, 141.34, 141.29, 139.8, 139.6, 138.2, 137.8, 137.7, 137.0, 136.8, 136.5, 129.1, 128.8, 128.7, 128.6, 128.53, 128.51, 128.49, 128.3, 128.1, 127.1, 126.3, 126.2, 122.7, 53.2, 50.8, 35.4, 35.1, 35.0, 34.2, 31.6, 31.4. HRMS (m/z, ESI-TOF): Calcd for C₂₂H₂₁ClN₂ONa⁺ [M+Na⁺] 387.1235, found 387.1235.

Preparation of 3-(2-fluoropyridin-3-yl)benzyl 3-phenylpropanoate:



To a solution of (3-bromophenyl)methanol (2.0 mmol), hydrocinnamoyl chloride (2.4 mmol) and triethylamine (6.0 mmol) in DCM (10 mL) at room temperature stirred for 6 h . Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-2:1) as the eluent to give 3-bromobenzyl 3-phenylpropanoate.

To a solution of 3-bromobenzyl 3-phenylpropanoate (1.0 mmol), $PdCl_2(PPh_3)_2$ (0.01 mmol), (2-fluoropyridin-3-yl)boronic acid (1.1 mmol) and K_2CO_3 (4.0 mmol) in 1,4-dioxane: $H_2O = 4$ mL: 1 mL under nitrogen atmosphere at 100 °C stirred for 12 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined

organic phase was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-3:1) as the eluent to give 3-(2-fluoropyridin-3-yl)benzyl 3-phenylpropanoate.



3-(2-fluoropyridin-3-yl)benzyl 3-phenylpropanoate (1a9)

¹H NMR (400 MHz, Chloroform-*d*) δ 8.24 (d, *J* = 3.8 Hz, 1H), 7. 90 – 7.85 (m, 1H), 7.59 – 7.51 (m, 2H), 7.48 (t, *J* = 7.6 Hz, 1H), 7.38 (d, *J* = 7.7 Hz, 1H), 7.32 – 7.27 (m, 3H), 7.24 – 7.16 (m, 3H), 5.20 (s, 2H), 3.02 (t, *J* = 7.7 Hz, 2H), 2.74 (t, *J* = 7.7 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.7, 160.4 (d, *J*_{C-F} = 240.3 Hz), 146.6 (d, *J*_{C-F} = 14.7 Hz), 140.8, 140.3, 136.6, 134.2 (d, *J*_{C-F} = 4.9 Hz), 129.0, 128.7 (d, *J*_{C-F} = 3.1 Hz), 128.6 (d, *J*_{C-F} = 2.9 Hz), 128.5, 128.31, 128.27, 126.3, 123.5 (d, *J*_{C-F} = 28.3 Hz), 121.9 (d, *J*_{C-F} = 4.4 Hz), 66.0, 35.8, 30.9. HRMS (m/z, ESI-TOF): Calcd for C₂₁H₁₈FNO₂Na⁺ [M+Na⁺] 358.1214, found 358.1215.



N-(2-(2-fluoropyridin-3-yl)benzyl)-*N*-methyl-3-phenylpropanamide (1a₁₀)

The general procedure I was followed. Yield: 244 mg, (70 %). Two rotamers can be observed on the NMR spectrum and the ratio is about 61:39.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.25 (dd, J = 13.5, 4.8 Hz, 1H), 7.73 – 7.59 (m, 1H), 7.43 – 7.08 (m, 10H), 4.52 (s, 1.23H), 4.27 (br, 0.72H), 2.93 (t, J = 7.9 Hz, 2H), 2.88 (s, 1.12H), 2.72 (s, 1.72H), 2.80 – 2.56 (m, 1.18H), 2.54 – 2.47 (m, 0.85H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.8, 172.2, 160.3(d, $J_{C-F} = 237.7$ Hz), 160.1 (d, $J_{C-F} = 237.9$ Hz), 147.5 (d, $J_{C-F} = 14.4$ Hz), 147.0 (d, $J_{C-F} = 14.3$ Hz), 142.0 (d, $J_{C-F} = 4.4$ Hz), 141.8 (d, $J_{C-F} = 4.4$ Hz), 141.3, 141.1, 135.6, 135.0, 133.3 (d, $J_{C-F} = 3.5$ Hz), 132.7 (d, $J_{C-F} = 3.3$ Hz), 130.8, 130.5, 129.4, 129.1, 128.50, 128.49, 128.45, 128.1, 127.8, 127.4, 126.2, 126.1, 125.9, 122.8 (d, $J_{C-F} = 32.2$ Hz), 122.3 (d, $J_{C-F} = 32.5$ Hz), 121.9 (d, $J_{C-F} = 4.3$ Hz), 121.6 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz), 48.4 (d, $J_{C-F} = 4.4$ Hz), 51.1 (d, $J_{C-F} = 4.1$ Hz)

= 2.4 Hz), 35.1, 34.8, 34.6, 34.1, 31.5, 31.2. HRMS (m/z, ESI-TOF): Calcd for $C_{22}H_{21}FN_2ONa^+$ [M+Na⁺] 371.1530, found 371.1530.



N-(3-(2-fluoropyridin-3-yl)phenethyl)-*N*-methyl-3-phenylpropanamide (1a₁₁)

The general procedure I was followed. Yield: 272 mg, (75 %).Two rotamers can be observed on the NMR spectrum and the ratio is about 57:43.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.27 – 8.25 (m, 1H), 7.97 – 7.92 (m, 0.57H), 7.89 – 7.84 (m, 0.44H), 7.55 – 7.42 (m, 3H), 7.39 – 7.27 (m, 5H), 7.20 (dd, *J* = 27.2, 7.5 Hz, 2H), 3.77 – 3.66 (m, 1.14H), 3.58 (t, *J* = 7.0 Hz, 0.85H), 3.07 – 2.95 (m, 3.69H), 2.93 – 2.87 (m, 3.40H), 2.67 (t, *J* = 7.9 Hz, 1.14H), 2.45 – 2.36 (m, 0.87H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.2, 172.1, 160.4 (d, *J*_{C-F} = 240.1 Hz), 160.3 (d, *J*_{C-F} = 240.3 Hz), 146.5, 146.4, 146.2, 141.4 (d, *J*_{C-F} = 2.9 Hz), 140.8 (d, *J*_{C-F} = 4.5 Hz), 139.8, 138. 9, 134.4 (d, *J*_{C-F} = 5.1 Hz), 134.1 (d, *J*_{C-F} = 4.8 Hz), 129.3 (d, *J*_{C-F} = 2.9 Hz), 129.22 (d, *J*_{C-F} = 3.0 Hz), 126.9 (d, *J*_{C-F} = 3.0 Hz), 126.1, 126.0, 124.0, 123.7, 123.4, 121.94 (d, *J*_{C-F} = 4.4 Hz), 121.88 (d, *J*_{C-F} = 4.5 Hz), 51.4, 49.9, 36.0, 35.5, 34.71, 34.70, 33.6, 31.4, 31.2. HRMS (m/z, ESI-TOF): Calcd for C₂₃H₂₃FN₂O Na⁺ [M+Na⁺] 385.1687, found 385.1686.



N-(2-(2-fluoropyridin-3-yl)phenethyl)-*N*-methyl-3-phenylpropanamide (1a₁₂)

The general procedure I was followed. Yield: 236 mg, (65 %).Two rotamers can be observed on the NMR spectrum and the ratio is about 52:48.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.30 (d, *J* = 4.7 Hz, 0.52H), 8.16 (d, *J* = 4.7 Hz, 0.48H), 7.79 (t, *J* = 9.1 Hz, 0.53H), 7.60 (t, *J* = 7.7 Hz, 0.51H), 7.45 – 7.27 (m, 6H), 7.24 – 7.17 (m, 3H), 7.14 (d, *J* = 7.5 Hz, 1H), 3.46 (t, *J* = 8.0 Hz, 1H), 3.27 (t, *J* = 7.2 Hz, 1H), 2.94 (t, *J* = 8.0 Hz, 1H), 2.82 (t, *J* = 8.0 Hz, 1H), 2.77 – 2.72 (m, 3.54H), 2.67

(s, 1.56H), 2.55 (t, J = 7.6 Hz, 1H), 2.16 (t, J = 7.8 Hz, 1H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 171.8, 160.5 (d, J = 238.8 Hz), 160.2 (d, J = 238.7 Hz),147.2 (d, J = 14.3 Hz), 147.0 (d, J = 14.2 Hz), 142.4 (d, J = 4.6 Hz), 142.0 (d, J = 4.4 Hz), 141.41, 141.37, 137.5, 136.7, 133.8 (d, J = 3.7 Hz), 133.6 (d, J = 3.6 Hz), 130.7, 130.4, 129.97, 129.95, 129.2, 128.9, 128.52, 128.48, 128.45, 128.4, 127.2, 126.6, 126.12, 126.09, 123.5 (d, J = 32.2 Hz), 123.2 (d, J = 32.3 Hz), 121.7 (d, J = 4.3 Hz), 121.6 (d, J = 4.3 Hz), 50.7, 49.0, 35.6, 35.4, 34.3, 33.4, 32.1, 31.3, 31.2, 30.8. HRMS (m/z, ESI-TOF): Calcd for C₂₃H₂₃FN₂ONa⁺ [M+Na⁺] 385.1687, found 385.1687.



N-(3-(2-fluoropyridin-3-yl)phenyl)-*N*-methyl-3-phenylpropanamide (1a₁₃)

The general procedure I was followed. Yield: 234 mg, (70 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.21 (s, 1H), 7.81 (t, *J* = 8.5 Hz, 1H), 7.54 – 7.42 (m, 2H), 7.31 – 7.28 (m, 1H), 7.22 – 7.01 (m, 7H), 3.28 (s, 3H), 2.93 (t, *J* = 7.6 Hz, 2H), 2.43 (t, *J* = 7.7 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 160.1 (d, *J*_{C-F} = 240.1 Hz), 146.8 (d, *J*_{C-F} = 14.9 Hz), 144.3, 141.0, 140.6 (d, *J*_{C-F} = 4.1 Hz), 135.5, 130.1, 128.4, 128.3, 128.0, 127.7, 127.2, 126.0, 122.6 (d, *J*_{C-F} = 28.3 Hz), 121.9 (d, *J*_{C-F} = 4.5 Hz), 37.3, 35.9, 31.7. HRMS (m/z, ESI-TOF): Calcd for C₂₁H₁₉FN₂ONa⁺ [M+Na⁺] 357.1374, found 357.1373.



N-methyl-3-phenyl-*N*-(3-(pyrimidin-5-yl)phenyl)propanamide (1a₁₄)

The general procedure I was followed. Yield: 160 mg, (50 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 9.18 (s, 1H), 8.84 (s, 21H), 7.48 (d, J = 4.7 Hz, 2H), 7.16 – 7.01 (m, 7H), 3.26 (s, 3H), 2.89 (t, J = 7.5 Hz, 2H), 2.37 (t, J = 7.5 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 157.8, 154.8, 145.0, 141.0, 136.0, 133.1, 130.8, 128.40, 128.3, 127.8, 126.2, 126.1, 125.8, 37.4, 35.9, 31.7. HRMS (m/z, ESI-TOF): Calcd for C₂₀H₁₉N₃ONa⁺ [M+Na⁺] 340.1420, found 340.1420.



N-(3-(2-fluoropyridin-3-yl)benzyl)-*N*-((4-nitrophenyl)sulfonyl)-3phenylpropanamide (1a₁₅)

The general procedure II was followed. Yield: 468 mg, (90 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.26 – 8.17 (m, 3H), 7.89 (d, J = 8.8 Hz, 2H), 7.82 – 7.77 (m, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.46 – 7.41 (m, 2H), 7.32 – 7.27 (m, 2H), 7.17 – 7.11 (m, 3H), 7.01 – 6.94 (m, 2H), 5.14 (s, 2H), 2.93 – 2.78 (m, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.4, 160.3 (d, $J_{C-F} = 239.9$ Hz), 150.5, 146.8 (d, $J_{C-F} =$ 14.9 Hz), 144.8, 140.8 (d, $J_{C-F} = 4.3$ Hz), 139.8, 136.5, 134.7 (d, $J_{C-F} = 5.0$ Hz), 129.5, 128.7 (d, J = 3.0 Hz), 128.6, 128.4, 127.9 (d, $J_{C-F} = 3.1$ Hz), 127.6, 126.5, 124.2, 123.2 (d, $J_{C-F} = 28.2$ Hz), 122.1 (d, $J_{C-F} = 4.4$ Hz), 49.5, 38.1, 30.5. HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₂FN₃O₅S Na⁺ [M+Na⁺] 542.1156, found 542.1157.

2.2 Synthesis of Directing Template.



To a stirred solution of (3-bromophenyl)methanamine (10.0 mmol) in anhydrous DCM (20 mL) at , The mixture was cooled to 0 °C and benzenesulfonyl chloride (11.0 mmol) was added dropwise. The mixture was allowed to warm to room temperate and stirred for 2 h. The crude reaction mixture was diluted with EtOAc (40 mL) and filtered through a short pad of Celite. The filtrate was concentrated in vacuo and purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-3:1) as the eluent to give N-(3-bromobenzyl)benzenesulfonamide (99%).

To a solution of *N*-(3-bromobenzyl)benzenesulfonamide (5.0 mmol), $PdCl_2(dppf)$ (0.15 mmol), (2-chloropyridin-3-yl)boronic acid (5.5 mmol) and K_2CO_3 (20.0 mmol) in 1,4-dioxane:H₂O = 25 mL:10 mL under nitrogen atmosphere at 100 °C stirred for 12 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (3:1-2:1) as the eluent to give *N*-(3-(2-chloropyridin-3-yl) - benzyl)benzenesulfonamide (7) (70%). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.33 (dd, J = 4.9, 1.9 Hz, 1H), 7.82 (d, J = 7.5 Hz, 2H), 7.56 – 7.47 (m, 2H), 7.44 – 7.41 (m, 2H), 7.32 – 7. 29 (m, 2H), 7.25 – 7.18 (m, 3H), 5.37 (t, J = 6.3 Hz, 1H), 4.18 (d, J = 6.3 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 149.5, 148.6, 140.0, 139.8, 137. 9, 136.8, 136.5, 132.8, 129.2, 128. 9, 128.8, 128.7, 127. 9, 127.1, 122.7, 47.1. HRMS (m/z, ESI-TOF): Calcd for C₁₈H₁₅ClN₂O₂SNa⁺ [M+Na⁺] 381.0435, found 381.0434.

2.3 Synthesis of Substrates.

General Procedure i



To a stirred solution of substituted phenylpropionic acid (1.2 mmol) in anhydrous DCM (5 mL) under nitrogen atmosphere was added DMF (20 uL). The mixture was cooled to 0 °C and oxalyl chloride (203 uL, 2.4 mmol) was added dropwise. The mixture was allowed to warm to room temperate and stirred for 2 h. Then volatile matter was removed under reduced pressure. The residue was re-dissolved with anhydrous THF (5 mL) and kept under N₂ atmosphere, which was used in following operation without further purification.

To a dry round bottom flask under N₂ atmosphere was charged with 7 (1.0 mmol), DMAP (0.1 mmol) and NaH (60% dispersion in mineral oil, 3 mmol). The bottom was placed into an ice bath for 10 minutes followed by addition of anhydrous THF (5 mL). After stirred for 0.5 h at 0 °C, the acyl chloride prepared above was added dropwise to the mixture. The reaction was allowed to warm to room temperate and stirred for 12 h. H₂O was slowly added (be careful!!) to quench the reaction. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-3:1) as the eluent to give desired compound. (60 % - 95 %)

General Procedure ii



To a stirred solution of substituted benzyl alcohol (1.0 mmol) in anhydrous DCM (5 mL) under nitrogen atmosphere was added BTC (Triphosgene) (0.33 mmol). The mixture was cooled to 0 °C and pyridine (1.0 mmol) was added dropwise. The mixture was allowed to warm to room temperate and stirred for 2 h. Then volatile matter was removed under reduced pressure. The residue was re-dissolved with anhydrous THF (5 mL) and kept under N₂ atmosphere, which was used in following operation without further purification.

To a dry round bottom flask under N₂ atmosphere was charged with 7 (1.0 mmol), DMAP (0.1 mmol) and NaH (60% dispersion in mineral oil, 3 mmol). The bottom was placed into an ice bath for 10 minutes followed by addition of anhydrous THF (5 mL). After stirred for 0.5 h at 0 °C, the acyl chloride prepared above was added dropwise to the mixture. The reaction was allowed to warm to room temperate and stirred for 12 h. H₂O was slowly added (be careful!!) to quench the reaction. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-3:1) as the eluent to give desired compound. (20 % - 70 %)



N-(3-(2-chloropyridin-3-yl)benzyl)-3-phenyl-N-(phenylsulfonyl)propanamide

(1a₈). The general procedure **i** was followed. Yield: 466 mg, (95 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 2.0 Hz, 1H), 7.74 – 7.66 (m, 2H), 7.62-7.57 (m, 2H), 7.45 (t, *J* = 7.9 Hz, 2H), 7.41-7.37 (m, 4H), 7.31 (dd, *J* = 7.6, 4.8 Hz, 1H), 7.20 – 7.09 (m, 3H), 7.03 – 6.94 (m, 2H), 5.13 (s, 2H), 2.97 – 2.90 (m, 2H), 2.88 – 2.84 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.5, 149.7, 148.6, 140.1, 139.8, 139.6, 137.9, 137.0, 136.6, 133.9, 129.3, 128.90, 128.88, 128.8, 128.6, 128.3, 128.1, 127.7, 126.3, 122.7, 49.2, 38.1, 30.7. HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₃ClN₂O₃SNa⁺ [M+Na⁺] 513.1010, found 513.1011.



N-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)-3-(o-tolyl)propanamide (1b). The general procedure **i** was followed. Yield: 403 mg, (80 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 2.0 Hz, 1H), 7.77 – 7.71 (m, 2H), 7.64 – 7.56 (m, 2H), 7.50 – 7.38 (m, 6H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.06 (d, J = 4.4 Hz, 2H), 7.02 – 6.98 (m, 1H), 6.89 (d, J = 7.4 Hz, 1H), 5.17 (s, 2H), 2.87 (s, 4H), 2.13 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.5, 149.5, 148.5, 139.7, 139.5, 138.1, 137.8, 136.9, 136.5, 135. 9, 133.8, 130.3, 129.2, 128.8, 128.7, 128.4, 127.9, 127.6, 126.4, 126.0, 122.6, 49.2, 36.6, 28.0, 19.1. HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₅ClN₂O₃SNa⁺ [M+Na⁺] 527.1167, found 527.1165.



3-(2-chlorophenyl)-*N***-(3-(2-chloropyridin-3-yl)benzyl)-***N* (phenylsulfonyl)propanamida (1c). The general procedure **i** was followed. Yield: 471 mg, (90 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.38 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.75 – 7.68 (m, 2H), 7.62 – 7.54 (m, 2H), 7.47 – 7.35 (m, 6H), 7.29 (dd, *J* = 7.6, 4.8 Hz, 1H), 7.22 (d, *J* = 7.4 Hz, 1H), 7.09 – 7.03 (m, 3H), 5.15 (s, 2H), 3.02 – 2.88 (m, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.3, 149.6, 148.6, 139.8, 139.5, 137.9, 137.6, 136.9, 136.6, 133.9, 133.8, 130.7, 129.5, 129.3, 128.9, 128.8, 128.0, 127.94, 127.7, 126.9, 122.7, 49.3, 36.2, 28.7. HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₂Cl₂N₂O₃SNa⁺ [M+Na⁺] 547.0620, found 547.0621.



N-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)-3-(2-(trifluoromethoxy) - phenyl)propanamide (1d). The general procedure **i** was followed. Yield: 430 mg, (75 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.73 – 7.68 (m, 2H), 7.62 – 7.57 (m, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.41 – 7.38 (m, 4H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 7.20 – 7.10 (m, 2H), 7.08 (d, J = 4.1 Hz, 2H), 5.15 (s, 2H), 2.92 (s, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.2, 149.7, 148.6, 147.6 (d, $J_{C-F} = 1.6$ Hz), 139.8, 139.5, 137.9, 137.0, 136.6, 134.0, 132.5, 131.0, 129.4, 128.9, 128.9, 128.8, 128.1, 128.0, 127.6, 126.9, 122.7, 120.6 (q, $J_{C-F} = 257.5$ Hz), 120.4 (d, $J_{C-F} = 1.8$ Hz), 49.4, 36.6, 25.1. HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₂ClF₃N₂O₄SNa⁺ [M+Na⁺] 597.0833, found 597.0833.



N-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)-3-(2-(trifluoromethyl) - phenyl)propanamide (1e₁). The general procedure **i** was followed. Yield: 390 mg, (70 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.75 – 7.68 (m, 2H), 7.64 – 7.52 (m, 3H), 7.48 – 7.38 (m, 6H), 7.37 – 7.28 (m, 2H), 7.25 – 7.23 (m, 1H), 7.13 (d, *J* = 7.6 Hz, 1H), 5.16 (s, 2H), 3.05 (t, *J* = 7.6 Hz, 2H), 2.91 (t, *J* = 7.6 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 149.7, 148.6, 139.8, 139.5, 138.9 (d, *J*_{C-F} = 1.8 Hz), 137.9, 136.9, 136.6, 134.0, 132.0, 131.2, 129.3, 128.92, 128.86, 128.8, 128.5 (d, *J*_{C-F} = 29.9 Hz), 128.1, 127.7, 126.6, 126.2 (q, *J*_{C-F} = 5.8 Hz), 124.5 (q, *J*_{C-F} = 273.8 Hz), 122.7, 49.4, 38.2, 27.6 (d, *J*_{C-F} = 2.0 Hz). HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₂ClF₃N₂O₃SNa⁺ [M+Na⁺] 581.0884, found 581.0884.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-(2-methoxyphenyl)-*N*-(phenylsulfonyl)propanamide (1e₂). The general procedure **i** was followed. Yield: 416 mg, (80 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.36 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.75 (d, *J* = 7.2 Hz, 2H), 7.61 – 7.53 (m, 2H), 7.46 – 7.36 (m, 6H), 7.28 (dd, *J* = 7.6, 4.9 Hz, 1H), 7.12 (td, *J* = 7.8, 1.8 Hz, 1H), 6.96 (dd, *J* = 7.4, 1.7 Hz, 1H), 6.79 – 6.71 (m, 2H), 5.15 (s, 2H), 3.63 (s, 3H), 2.95 – 2.81 (m, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.8, 157.2, 148.4, 139.6, 139.4, 137.6, 136.9, 133.6, 129.9, 128.9, 128.59, 128.56, 128.4, 128.0, 127.63, 127.59, 127.57, 122.6, 120.3, 110.0, 54.9, 49.1, 36.0, 25.8. HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₅ClN₂O₄SNa⁺ [M+Na⁺] 543.1116, found 543.1114.



N-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)-3-(m-tolyl)propanamide (1f). The general procedure **i** was followed. Yield: 403 mg, (80 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 2.0 Hz, 1H), 7.76 – 7.69 (m, 2H), 7.64 – 7.56 (m, 2H), 7.45 (t, J = 7.9 Hz, 2H), 7.41 – 7.37 (m, 4H), 7.30 (dd, J = 7.5, 4.8 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.95 (d, J = 7.6 Hz, 1H), 6.82 (s, 1H), 6.79 (d, J = 7.5 Hz, 1H), 5.15 (s, 2H), 2.97 – 2.88 (m, 2H), 2.88 – 2.79 (m, 2H), 2.25 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.5, 149.6, 148.6, 140.0, 139.7, 139.6, 138.0, 137.8, 137.0, 133.8, 129.2, 129.1, 128.82, 128.78, 128.76, 128.4, 128.0, 127.7, 127.0, 125.2, 122.7, 49.2, 38.1, 30.5, 21.4. HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₅ClN₂O₃SNa⁺ [M+Na⁺] 527.1167, found 527.1164.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-(3-methoxyphenyl)-*N*-(phenylsulfonyl)-

propanamide (1g). The general procedure **i** was followed. Yield: 443 mg, (85 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.38 (dd, J = 4.8, 2.0 Hz, 1H), 7.75 – 7.69 (m, 2H), 7.62 – 7.54 (m, 2H), 7.44 (t, J = 7.9 Hz, 2H), 7.40 – 7.38 (m, 4H), 7.29 (dd, J =7.6, 4.7 Hz, 1H), 7.07 (t, J = 8.1 Hz, 1H), 6.71 – 6.65 (m, 1H), 6.60 – 6.54 (m, 2H), 5.14 (s, 2H), 3.71 (s, 3H), 2.94 – 2.90 (m, 2H), 2.86 – 2.82 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.4, 159.6, 149.5, 148.5, 141.7, 139.7, 139.5, 137.8, 136.9, 136.5, 133.8, 129.4, 129.2, 128.8, 128.71, 128.70, 127.9, 127.6, 122.6, 120.5, 114.0, 111.6, 55.1, 49.2, 37.9, 30.6. HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₅ClN₂O₄SNa⁺ [M+Na⁺] 543.1116, found 543.1114.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-(3-fluorophenyl)-N-(phenylsulfonyl)-

propanamide (1h). The general procedure **i** was followed. Yield: 460 mg, (91 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.71 – 7.65 (m, 2H), 7.60 (td, J = 7.6, 1.6 Hz, 2H), 7.46 (t, J = 7.9 Hz, 2H), 7.42 – 7.37 (m, 4H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 7.10 (td, J = 7.9, 6.0 Hz, 1H), 6.81 (td, J = 8.5, 2.6 Hz, 1H), 6.76 (dd, J = 7.5, 1.5 Hz, 1H), 6.64 (dt, J = 9.9, 2.1 Hz, 1H), 5.14 (s, 2H), 2.96 – 2.89 (m, 2H), 2.88 – 2.84(m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.2, 162.9 (d, $J_{C-F} = 246$ Hz), 149.7, 148.7, 142.7 (d, $J_{C-F} = 7$ Hz), 139.8, 139.6, 138.0, 137.0, 136.7, 134.0, 123.0 (d, $J_{C-F} = 8$ Hz), 129.4, 129.02, 129.00, 128.9, 128.2, 127.7, 124.1 (d, $J_{C-F} = 3$ Hz), 122.7, 115.2 (d, $J_{C-F} = 21$ Hz), 113.3 (d, $J_{C-F} = 21$ Hz), 49.3, 37.9, 30.4 (d, $J_{C-F} = 1.8$ Hz). HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₂CIFN₂O₃SNa⁺ [M+Na⁺] 531.0916, found 531.0916.



3-(3-chlorophenyl)-N-(3-(2-chloropyridin-3-yl)benzyl)-N-(phenylsulfonyl)-

propanamide (1i). The general procedure **i** was followed. Yield: 315 mg, (60 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.71 – 7.65 (m, 2H), 7.64 – 7.58 (m, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.43 – 7.35 (m, 4H), 7.31 (dd, J =7.6, 4.8 Hz, 1H), 7.12 – 7.04 (m, 2H), 6.94 (s, 1H), 6.87 (dt, J = 6.8, 1.9 Hz, 1H), 5.14 (s, 2H), 2.94 – 2.90 (m, 2H), 2.86 – 2.82 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 149.7, 148.7, 142.3, 139.8, 139.6, 137.9, 137.0, 136.7, 134.2, 134.1, 129.8, 129.4, 129.01, 129.00, 128.9, 128.5, 128.2, 127.6, 126.7, 126.6, 122.7, 49.3, 37.9, 30.3. HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₂Cl₂N₂O₃SNa⁺ [M+Na⁺] 547.0620, found 547.0620.

CI OCF₃

N-(3-(2-chloropyridin-3-yl)benzyl)-N-(phenylsulfonyl)-3-(3-(trifluoromethoxy)-

phenyl)propanamide (1j). The general procedure i was followed. Yield: 460 mg, (80 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.71 – 7.66 (m, 2H), 7.65 – 7.56 (m, 2H), 7.46 (t, J = 7.9 Hz, 2H), 7.42 – 7.37 (m, 4H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 7.18 (t, J = 7.9 Hz, 1H), 6.99 (d, J = 8.2 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 6.82 (s, 1H), 5.15 (s, 2H), 3.03 – 2.79 (m, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 149.7, 149.4, 148.7, 142.6, 139.8, 139.6, 138.0, 137.0, 136.6, 134.1, 129.9, 129.4, 129.1, 129.0, 128.9, 128.2, 127.6, 126.9, 122.7, 120.9, 120.5 (d, $J_{C-F} = 256.8$ Hz), 118.8, 49.3, 37.8, 30.3. HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₂ClF₃N₂O4SNa⁺ [M+Na⁺] 597.0833, found 597.0834.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-phenyl-*N*-(phenylsulfonyl)butanamide (1k). The general procedure **i** was followed. Yield: 428 mg, (85 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 2.0 Hz, 1H), 7.69 – 7.63 (m, 2H), 7.63 – 7.56 (m, 2H), 7.46 (t, J = 7.9 Hz, 2H), 7.40 – 7.35 (m, 2H), 7.34 – 7.27 (m, 3H), 7.16 – 7.05 (m, 3H), 6.94 (d, J = 6.9 Hz, 2H), 5.16 – 5.02 (m, 2H), 3.32 (h, J = 7.0 Hz, 1H), 2.96 (dd, J = 16.6, 7.3 Hz, 1H), 2.83 (dd, J = 16.6, 7.0 Hz, 1H), 1.12 (d, J = 7.0 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.0, 149.7, 148.6, 145.4, 139.80, 139.77, 137.9, 137.1, 136.7, 133.9, 129.3, 128.91, 128.87, 128.8, 128.5, 128.2, 127.7, 126.7, 126.4, 122.7, 49.0, 44.7, 36.1, 21.8. HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₅ClN₂O₃SNa⁺ [M+Na⁺] 527.1167, found 527.1168.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-phenyl-*N*-(phenylsulfonyl)pentanamide (11). The general procedure **i** was followed. Yield: 440 mg, (85 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, *J* = 4.8, 2.0 Hz, 1H), 7.65 – 7.55 (m, 4H), 7.49 – 7.43 (m, 2H), 7.40 – 7.33 (m, 2H), 7.31 (dd, *J* = 7.5, 4.7 Hz, 1H), 7.27 – 7.26 (m, 1H), 7.22 (dt, *J* = 7.1, 1.8 Hz, 1H), 7.13 – 7.01 (m, 3H), 6.90 – 6.83 (m, 2H), 5.20 – 4.95 (m, 2H), 3.11 – 2.82 (m, 3H), 1.60 – 1.49 (m, 1H), 1.46 – 1.35 (m, 1H),

0.67 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 149.7, 148.6, 143.7, 139.84, 139.83, 137.9, 137.2, 136.7, 133.8, 129.3, 128.92, 128.88, 128.8, 128.4, 128.2, 127.7, 127.5, 126.4, 122.7, 48.9, 43.5, 43.3, 29.0, 12.0. HRMS (m/z, ESI-TOF): Calcd for C₂₉H₂₇ClN₂O₃SNa⁺ [M+Na⁺] 541.1323, found 541.1323.



N-(3-(2-chloropyridin-3-yl)benzyl)-2-(1,3-dioxoisoindolin-2-yl)-3-phenyl-*N*-(phenylsulfonyl)propanamide (1m). The general procedure **i** was followed. Yield: 381 mg, (60 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.31 (dd, J = 4.8, 2.0 Hz, 1H), 7.91 (dd, J = 7.4, 1.8 Hz, 2H), 7.63 – 7.49 (m, 6H), 7.43 (t, J = 7.6, Hz, 2H), 7.27 – 7.17 (m, 5H), 7.14 – 7.09 (m, 2H), 7.08 – 6.99 (m, 3H), 5.90 (dd, J = 10.9, 4.8 Hz, 1H), 4.89 (q, J = 16.0 Hz, 2H), 3.63 (dd, J = 13.9, 10.9 Hz, 1H), 3.48 (dd, J = 13.9, 4.8 Hz, 1H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.1, 167.8, 149.6, 148.6, 139.8, 138.6, 137.6, 136.5, 136.4, 136.0, 134.19, 134.15, 131.4, 129.4, 129.1, 128.8, 128.61, 128.59, 128.4, 128.1, 127.5, 127.0, 123.4, 122.7, 56.6, 50.0, 34.9. HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₆ClN₃O₅SNa⁺ [M+Na⁺] 658.1174, found 658.1174.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-(2,6-dimethylphenyl)-*N*-(phenylsulfonyl)propanamide (1n) . The general procedure **i** was followed. Yield: 466 mg, (90 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.9, 1.9 Hz, 1H), 7.79 – 7.72 (m, 2H), 7.66 – 7.58 (m, 2H), 7.50 – 7.41 (m, 6H), 7.32 (dd, J = 7.6, 4.7 Hz, 1H), 7.03 – 6.90 (m, 3H), 5.18 (s, 2H), 2.91 – 2.84 (m, 2H), 2.73 – 2.64 (m, 2H), 2.10 (s, 6H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.9, 149.7, 148.7, 139.8, 139.6, 138.0, 137.0, 136.8, 136.6, 136.3, 134.0, 129.4, 128.97, 128.95, 128.7, 128.4, 127.9, 127.8, 126.4, 122.7, 49.5, 35.5, 24.9, 19.7. HRMS (m/z, ESI-TOF): Calcd for C₂₉H₂₇ClN₂O₃SNa⁺ [M+Na⁺] 541.1323, found 541.1322.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-(3,5-difluorophenyl)-*N*-(phenylsulfonyl)propanamide (10). The general procedure **i** was followed. Yield: 447 mg, (85 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, *J* = 4.8, 2.0 Hz, 1H), 7.71 – 7.64 (m, 2H), 7.64 – 7.57 (m, 2H), 7.46 (t, *J* = 7.8 Hz, 2H), 7.41 – 7.36 (m, 4H), 7.30 (dd, *J* = 7.5, 4.8 Hz, 1H), 6.54 (tt, *J* = 9.0, 2.4 Hz, 1H), 6.46 (h, *J* = 4.3 Hz, 2H), 5.15 (s, 2H), 2.93 – 2.89 (m, 2H), 2.85 – 2.82 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 162.9 (dd, *J*_{*C*-*F*} = 248.3, 12.9 Hz), 149.6, 148.6, 144.0 (t, *J*_{*C*-*F*} = 9.1 Hz), 139.8, 139.5, 137.9, 136.9, 136.5, 134.1, 129.4, 129.0, 128.8, 128.2, 127.5, 122.7, 111.2 (dd, *J*_{*C*-*F*} = 24.7, 11.5 Hz), 101.8 (t, *J*_{*C*-*F*} = 25.2 Hz), 49.2, 37.4, 30.2. HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₁ClF₂N₂O₃SNa⁺ [M+Na⁺] 549.0822, found 549.0819.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-(3-fluoro-2-methylphenyl)-N-

(**phenylsulfonyl**)-**propanamide** (1**p**). The general procedure **i** was followed. Yield: 418 mg, (80 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.73 – 7.65 (m, 2H), 7.64 – 7.57 (m, 2H), 7.51 – 7.38 (m, 6H), 7.32 (dd, *J* = 7.5, 4.8 Hz, 1H), 6.93 (td, *J* = 7.9, 5.8 Hz, 1H), 6.85 – 6.78 (m, 1H), 6.68 (d, *J* = 7.6 Hz, 1H), 5.16 (s, 2H), 2.89 – 2.81 (m, 4H), 2.00 (d, *J* = 2.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.4, 161.4 (d, *J*_{*C*-*F*} = 243.5 Hz), 149.7, 148.7, 140.8 (d, *J*_{*C*-*F*} = 4.1 Hz), 139.8, 139.6, 138.0, 137.0, 136.6, 134.0, 129.4, 129.00, 128.98, 128.9, 128.2, 127.6, 126.7 (d, *J*_{*C*-*F*} = 9.1 Hz), 124.2 (d, *J*_{*C*-*F*} = 3.1 Hz), 123.2 (d, *J*_{*C*-*F*} = 16.0 Hz), 122.7, 113.2 (d, *J*_{*C*-*F*} = 23.3 Hz), 49.4, 36.8, 27.9 (d, *J*_{*C*-*F*} = 2.8 Hz), 10.3 (d, *J*_{*C*-*F*} = 5.8 Hz). HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₄CIFN₂O₃SNa⁺ [M+Na⁺] 545.1072, found 545.1071.



N-(3-(2-chloropyridin-3-yl)benzyl)-3-(5-fluoro-2-methylphenyl)-N-

(**phenylsulfonyl**)-**propanamide** (1**q**). The general procedure **i** was followed. Yield: 444 mg, (85 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.74 – 7.69 (m, 2H), 7.65 – 7.57 (m, 2H), 7.47 (t, *J* = 7.8 Hz, 2H), 7.44 – 7.39 (m, 4H), 7.31 (dd, *J* = 7.6, 4.8 Hz, 1H), 6.99 (dd, *J* = 8.4, 5.9 Hz, 1H), 6.74 (td, *J* = 8.4, 2.8 Hz, 1H), 6.56 (dd, *J* = 9.8, 2.8 Hz, 1H), 5.17 (s, 2H), 2.92 – 2.75 (m, 4H), 2.09 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.3, 161.2 (d, *J*_{C-F} = 243.5 Hz), 149.7, 148.6, 140.3 (d, *J*_{C-F} = 7.0 Hz), 139.8, 139.6, 138.0, 137.0, 136.6, 134.0, 131.55 (d, *J*_{C-F} = 2.8 Hz), 131.51 (d, *J*_{C-F} = 7.6 Hz), 129.4, 129.01, 128.97, 128.9, 128.2, 127.6, 122.7, 115.1 (d, *J*_{C-F} = 21.1 Hz), 113.0 (d, *J*_{C-F} = 20.5 Hz), 49.4, 36.5, 28.0 (d, *J*_{C-F} = 1.6 Hz), 18.5. HRMS (m/z, ESI-TOF): Calcd for C₂₈H₂₄CIFN₂O₃SNa⁺ [M+Na⁺] 545.1072, found 545.1071.



3-(2-chloro-3-fluorophenyl)-N-(3-(2-chloropyridin-3-yl)benzyl)-N-

(**phenylsulfonyl**)-**propanamide** (1**r**). The general procedure **i** was followed. Yield: 434 mg, (80 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.7, 1.9 Hz, 1H), 7.71 – 7.66 (m, 2H), 7.65 – 7.55 (m, 2H), 7.48 – 7.36 (m, 6H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 7.00 (td, J = 7.9, 5.4 Hz, 1H), 6.93 (td, J = 8.5, 1.6 Hz, 1H), 6.86 (d, J = 7.5 Hz, 1H), 5.16 (s, 2H), 3.02 – 3.00 (m, 2H), 2.96 – 2.90 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.0, 158.3 (d, $J_{C-F} = 247.9$ Hz), 149.7, 148.6, 140.2, 139.8, 139.5, 137.9, 136.9, 136.6, 134.0, 129.4, 128.9, 128.82, 128.15, 127.6, 127.5, 127.4, 125.7 (d, $J_{C-F} = 3.3$ Hz), 122.7, 120.8 (d, $J_{C-F} = 17.3$ Hz), 114.6 (d, $J_{C-F} = 21.4$ Hz), 49.3, 36.0, 28.4 (d, $J_{C-F} = 2.6$ Hz). HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₁C₁₂FN₂O₃SNa⁺ [M+Na⁺] 565.0526, found 565.0524.



3-(3-chloro-5-fluorophenyl)-N-(3-(2-chloropyridin-3-yl)benzyl)-N-

(**phenylsulfonyl**)-**propanamide** (1s). The general procedure **i** was followed. Yield: 325 mg, (60 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.70 – 7.65 (m, 2H), 7.61 (td, J = 7.0, 6.2, 1.6 Hz, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.2 – 7.36 (m, 4H), 7.31 (dd, J = 7.6, 4.8 Hz, 1H), 6.84 (dt, J = 8.5, 2.1 Hz, 1H), 6.75 (s, 1H), 6.56 (d, J = 9.3 Hz, 1H), 5.15 (s, 2H), 2.91 (t, J = 7.3 Hz, 2H), 2.83 (t, J = 6.7 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 162.6 (d, $J_{C-F} = 249.4$ Hz), 149. 7, 148.6, 143.9 (d, $J_{C-F} = 8.2$ Hz), 139.8, 139.5, 137.9, 136.8, 136.6, 134.8 (d, $J_{C-F} = 10.9$ Hz), 134.1, 129.4, 129.04, 129.01, 128. 9, 128.2, 127.5, 124.4 (d, $J_{C-F} = 3.1$ Hz), 122.7, 114.2 (d, $J_{C-F} = 24.8$ Hz), 113. 9 (d, $J_{C-F} = 21.2$ Hz), 49.3, 37.5, 30.1 (d, $J_{C-F} = 1.8$ Hz). HRMS (m/z, ESI-TOF): Calcd for C₂₇H₂₁Cl₂FN₂O₃SNa⁺ [M+Na⁺] 565.0526, found 565.0529.



N-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)-[1,1'-biphenyl]-2carboxamide (5a). The general procedure **i** was followed. Yield: 350 mg, (65 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.43 – 8.41 (m, 1H), 7.70 (d, *J* = 7.9 Hz, 2H),

11 HMR (400 MHz, Chloroform-*a*) 0 8.43 – 8.41 (fit, 111), 7.70 (d, J = 7.9 Hz, 211), 7.62 (t, J = 7.5 Hz, 1H), 7.54 – 7.50 (m, 1H), 7.48 – 7.41 (m, 3H), 7.40 – 7.21 (m, 10H), 7.16 (d, J = 7.7 Hz, 1H), 7.02 (d, J = 7.5 Hz, 1H), 6.97 (s, 1H), 4.62 (br, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.1, 149.6, 148.6, 139.7, 139.0, 138.9, 138.8, 137.7, 136.7, 136.5, 134.0, 133.7, 130.7, 129.9, 129.1, 128.9, 128.84, 128.75, 128.7, 128.6, 128.5, 128.4, 128.1, 127.7, 127.4, 122.7, 50.5. HRMS (m/z, ESI-TOF): Calcd for C₃₁H₂₃ClN₂O₃SNa⁺ [M+Na⁺] 561.1010, found 561.1010.



N-(3-(2-chloropyridin-3-yl)benzyl)-2'-methyl-*N*-(phenylsulfonyl)-[1,1'-biphenyl]-2-carboxamide (5b). The general procedure **i** was followed. Yield: 386 mg, (70 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.42 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.65 – 7.53 (m, 4H), 7.45 (td, *J* = 7.5, 1.5 Hz, 1H), 7.40 (t, *J* = 7.9 Hz, 2H), 7.36 – 7.27 (m, 4H), 7.26 – 7.21 (m, 3H), 7.16 (d, *J* = 7.6 Hz, 1H), 7.12 – 7.06 (m, 4H), 4.73 (br, 2H), 2.07 (br, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.7, 149.6, 148.6, 139.8, 138.79, 138.78, 138.3, 137.7, 136.7, 136.5, 134.9, 133.6, 130.7, 130.6, 130.2, 128.80, 128.75, 128.7, 128.4, 128.20, 128.17, 127.9, 127.6, 127.3, 125.6, 122.7, 50.8, 20.1. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₅ClN₂O₃SNa⁺ [M+Na⁺] 575.1166, found 575.1167.



N-(3-(2-chloropyridin-3-yl)benzyl)-3'-methoxy-*N*-(phenylsulfonyl)-[1,1'biphenyl]-2-carboxamide (5c). The general procedure **i** was followed. Yield: 370 mg, (65 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.66 (d, J = 7.1 Hz, 2H), 7.57 (t, J = 7.5 Hz, 1H), 7.50 (dd, J = 7.5, 2.0 Hz, 1H), 7.45 – 7.34 (m, 4H), 7.33 – 7.26 (m, 3H), 7.24 – 7.14 (m, 2H), 7.11 (dd, J = 7.7, 1.4 Hz, 1H), 6.99 (d, J = 7.2 Hz, 1H), 6.96 (s, 1H), 6.92 – 6.83 (m, 3H), 4.65 (br, 2H), 3.71 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.1, 159.6, 149.6, 148.6, 140.3, 139.7, 139.0, 138.9, 137.6, 136.7, 136.5, 134.0, 133.7, 130.6, 129.94, 129.86, 128.85, 128.72, 128.70, 128.5, 128.39, 128.36, 127.6, 127.5, 122. 7, 121.1, 114.4, 114.0, 55.3, 50.6. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₅ClN₂O₄SNa⁺ [M+Na⁺] 591.1116, found 591.1113.



N-(**3**-(**2**-chloropyridin-3-yl)benzyl)-3'-fluoro-*N*-(phenylsulfonyl)-[1,1'-biphenyl]-**2**-carboxamide (5d). The general procedure **i** was followed. Yield: 333 mg, (60 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.66 (d, *J* = 7.4 Hz, 2H), 7.59 (t, *J* = 7.5 Hz, 1H), 7.51 (dd, *J* = 7.5, 1.9 Hz, 1H), 7.46 – 7.40 (m, 3H), 7.34 – 7.28 (m, 4H), 7.25 – 7.21 (m, 1H), 7.18 (dd, *J* = 7.9, 5.9 Hz, 1H), 7.13 (d, *J* = 7.7 Hz, 1H), 7.08 – 6.95 (m, 5H), 4.68 (br, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.7, 162.6 (d, *J*_{C-F} = 247.4 Hz), 149.6, 148.7, 141.0 (d, *J*_{C-F} = 7.5 Hz), 139.7, 138.8, 137.9 (d, *J*_{C-F} = 1.9 Hz), 137.7, 136.6, 136.5, 134.1, 133. 9, 130.7, 130.4 (d, *J*_{C-F} = 8.1 Hz), 130. 0, 128.8, 128.6, 128.5, 128.3, 127.8, 127.7, 124.8 (d, *J*_{C-F} = 2.9 Hz), 122.7, 115.9 (d, *J*_{C-F} = 22.1 Hz), 115.1 (d, *J*_{C-F} = 20.9 Hz), 50.6. HRMS (m/z, ESI-TOF): Calcd for C₃₁H₂₂CIFN₂O₃SNa⁺ [M+Na⁺] 579.0916, found 579.0915.



N-(3-(2-chloropyridin-3-yl)benzyl)-3',5'-difluoro-N-(phenylsulfonyl)-[1,1'-

biphenyl]-2-carboxamide (5e). The general procedure **i** was followed. Yield: 403 mg, (70 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.7, 1.9 Hz, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.59 (t, J = 7.5 Hz, 1H), 7.54 (dd, J = 7.6, 1.9 Hz, 1H), 7.48 – 7.39 (m, 3H), 7.37 – 7.27 (m, 4H), 7.25 (d, J = 6.5 Hz, 1H), 7.15 – 7.05 (m, 3H), 6.82 – 6.69 (m, 3H), 4.77 (br, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.3, 162.7 (dd, $J_{C-F} = 249.8$, 12.9 Hz), 149.6, 148.7, 142.1 (t, $J_{C-F} = 9.6$ Hz), 139.7, 138.8, 137.8, 137.2 (t, $J_{C-F} = 2.2$ Hz), 136.5, 136.4, 134.1, 134.0, 130.8, 129.8, 128.94, 128.93, 128.7, 128.64, 128.63, 128.2, 128.1, 127.8, 122.7, 112.2 (dd, $J_{C-F} = 25.9$, 11.0 Hz), 103.5 (t, $J_{C-F} = 25.0$ Hz), 50.5. HRMS (m/z, ESI-TOF): Calcd for C₃₁H₂₁ClF₂N₂O₃SNa⁺ [M+Na⁺] 597.0822, found 597.0821.



benzyl (3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamate (5f). The general procedure **ii** was followed. Yield: 394 mg, (80 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.42 (dd, J = 4.9, 1.9 Hz, 1H), 7.66 (d, J = 7.9 Hz, 2H), 7.59 (dd, J = 7.4, 1.9 Hz, 1H), 7.56 – 7.47 (m, 2H), 7.45 – 7.43 (m, 3H), 7.37 – 7.24 (m, 6H), 7.13 (d, J = 6.4 Hz, 2H), 5.16 (s, 2H), 5.11 (s, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 152.4, 149.7, 148.6, 139.8, 139.2, 137.8, 137.2, 136.7, 134.3, 133.6, 129.3, 129.0, 128.8, 128.7, 128.64, 128.62, 128.6, 128.5, 122.7, 69.5, 49.9. HRMS (m/z, ESI-TOF): Calcd for C₂₆H₂₁ClN₂O₄SNa⁺ [M+Na⁺] 515.0803, found 515.0803.



3-fluorobenzyl (3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamate¹ (5g).

The general procedure **ii** was followed. Yield: 357 mg, (70 %).

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (d, *J* = 3.8 Hz, 1H), 7.65 (d, *J* = 7.9 Hz, 2H), 7.59 (d, *J* = 7.5 Hz, 1H), 7.53 (t, *J* = 7.4 Hz, 1H), 7.50 – 7.39 (m, 4H), 7.35 (t, *J* = 7.8 Hz, 2H), 7.30 (dd, *J* = 7.5, 4.8 Hz, 1H), 7.20 (td, *J* = 7.9, 5.8 Hz, 1H), 6.95 (td, *J* = 8.5, 2.5 Hz, 1H), 6.89 (d, *J* = 7.5 Hz, 1H), 6.71 (d, *J* = 9.1 Hz, 1H), 5.15 (s, 3H), 5.07 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 162.7 (d, *J*_{C-F} = 246.9 Hz), 152.3, 149.7, 148.6, 139.8, 139.2, 137.9, 137.1, 136.8 (d, *J*_{C-F} = 7.4 Hz), 136.6, 133.7, 130.3 (d, *J*_{C-F} = 8.1 Hz), 129.2, 129.1, 128.80, 128.76, 128.5, 128.4, 123. 9 (d, *J*_{C-F} = 3.0 Hz), 122.7, 115.6 (d, *J*_{C-F} = 21.1 Hz), 115.1 (d, *J*_{C-F} = 21.9 Hz), 68.4 (d, *J*_{C-F} = 2.0 Hz), 50.0. HRMS (m/z, ESI-TOF): Calcd for C₂₆H₂₀CIFN₂O₄SNa⁺ [M+Na⁺] 533.0709, found 533.0709.



3-chlorobenzyl (**3-(2-chloropyridin-3-yl)benzyl**)(phenylsulfonyl)carbamate (5h). The general procedure **ii** was followed. Yield: 105 mg, (20 %).

¹H NMR (400 MHz, Chloroform-d) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.64 (d, J = 7.2 Hz, 2H), 7.59 (dd, J = 7.5, 2.0 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.51 – 7.39 (m, 4H), 7.35 (t, J = 7.9 Hz, 2H), 7.30 (dd, J = 7.6, 4.7 Hz, 1H), 7.28 – 7.21 (m, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.01 – 6.99 (m, 2H), 5.14 (s, 2H), 5.05 (s, 2H). ¹³C NMR (101 MHz, Chloroform-d) δ 152.3, 149.7, 148.6, 139.8, 139.2, 137.9, 137.1, 136.7, 136.4, 134.5, 133.8, 130.0, 129.3, 129.1, 128.9, 128.83, 128.80, 128.6, 128.40, 128.36, 126.5, 122.7, 68.4, 50.0. HRMS (m/z, ESI-TOF): Calcd for C₂₆H₂₁Cl₂N₂O₄S⁺ [M+H⁺] 527.0594, found 527.0596.

2.4 **Optimization of Reaction Conditions**



Table S1: Optimization by Varying Different Templates.

Reaction condition: **1a** (0.1 mmol), **2a** (2 equiv), $Pd(OAc)_2$ (10 mol %), AgOAc (2 equiv), 2-hydroxy-3-trifluoromethylpyridine(L₁) (20 mol %), HFIP (1.0 mL), 80 °C, 12 h. Yield and selectivity are based on ¹H NMR of the crude reaction mixture using CH₂Br₂ as internal standard; products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers. N.D.= no detected. *a*Ratios of two major products, C-H olefination sites not determined.

	DT + CO ₂ Et 2-hydroxy-3-trifluorom 2a	%), AgOAc (2 equiv) lethylpyridine (20 mol %) mL), 80 °C, 36 h. EtO ₂ C	$\begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 $
entry	solvents (1 mL)	3as yield (%) ^a	Ratio $(p:others)^a$
1	HFIP	75	10:1
2	TFE	60	7:1
3	AcOH	trace	-
4	TFA	0	-

Table S2: Optimization by Varying Different Solvents

Reaction condition: **1as** (0.1 mmol), **2a** (2 equiv), $Pd(OAc)_2$ (10 mol %), AgOAc (2 equiv), 2-hydroxy-3-trifluoromethylpyridine (20 mol %), solvents (1.0 mL), 80 °C, 36 h. *^a*Yield and selectivity are based on ¹H NMR of the crude reaction mixture using CH₂Br₂ as internal standard; products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers.

	DT + CO ₂ Et 2a [Pd] (10 mol % 2-hydroxy-3-trifluoror HFIP (1.0 m	a), AgOAc (2 equiv) nethylpyridine (20 mol %) L), 80 °C, 36 h. EtO ₂ C	DT 3a ₈ O DT O Cl N DT Cl N DT
entry	[Pd]	3as yield (%) ^a	Ratio $(p:others)^a$
1	$Pd(OAc)_2$	75	11:1
2	Pd(OTFA) ₂	61	9:1
3	PdCl ₂	46	9:1
4	Pd(MeCN) ₂ Cl ₂	50	11:1

Table S3: Optimization of Palladium Catalyst

.....

Reaction condition: **1a**₈ (0.1 mmol), **2a** (2 equiv), [Pd] (10 mol %), AgOAc (2 equiv), 2-hydroxy-3-trifluoromethylpyridine (20 mol %), HFIP (1.0 mL), 80 °C, 36 h. ^{*a*}Yield and selectivity are based on ¹H NMR of the crude reaction mixture using CH₂Br₂ as internal standard; products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers.

	Pd(OAc)₂ (DT +	10 mol %), [Ag] (3 equiv) oromethylpyridine (20 mol %) 0 mL), 90 °C, 18 h. EtO ₂ C	$ \begin{array}{c} $
entry	[Ag]	3a ⁸ yield (%) ^{<i>a</i>}	Ratio $(p:others)^a$
1	AgF_2	11	5:1
2	Ag_2SO_4	33	mess
3	Ag ₂ O	0	-
4	AgTFA	40	8:1
5	AgOBz	0	-
6	AgOPiv	30	6:1
7	Ag ₂ CO ₃	69	10:1
8	$AgSbF_6$	0	-
9	AgNO ₃	63	10:1
10	AgBF ₄	0	-
11	Ag ₃ PO ₄	20	4:1
12	AgPF ₆	0	-
13	Ag ₂ WO ₄	14	6:1
14	AgOTf	trace	10:1

Table S4: Optimization by Varying Different Ag Salts

Reaction condition: **1a**₈ (0.1 mmol), **2a** (2 equiv), Pd(OAc)₂ (10 mol%), [Ag] (3 equiv), 2-hydroxy-3-trifluoromethylpyridine (20 mol %), HFIP (1.0 mL), 90 °C, 18 h. ^{*a*}Yield and selectivity are based on ¹H NMR of the crude reaction mixture using CH₂Br₂ as internal standard; products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers.

	DT + CO ₂ Et 2-hydroxy-3-triflu HFIP (x 2a	10 mol %), [Ag] (3 equiv) oromethylpyridine (20 mol %) mL), 90 °C, 12 h. EtO ₂ C	$\begin{array}{c} O \\ O \\ D \\ \mathbf{J} \\ \mathbf{J}$
entry	[x mL]	3a ⁸ yield (%) ^{<i>a</i>}	Ratio $(p:others)^a$
1	0.5	65	7:1
2	1.0	70	10:1
3	1.5	90 $(79)^b$	15:1

Table S5: Optimization of Reaction Concentration

Reaction condition: **1a**₈ (0.1 mmol), **2a** (2 equiv), Pd(OAc)₂ (10 mol %), AgOAc (3 equiv), 2-hydroxy-3-trifluoromethylpyridine (20 mol %), HFIP (x mL), 90 °C, 12 h. ^{*a*}Yield and selectivity are based on ¹H NMR of the crude reaction mixture using CH₂Br₂ as internal standard; products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers. ^{*b*}Isolated yield.

$H = \frac{1}{p} \frac{1}{m} \frac{1}{1} $	DT + CO ₂ Et 2-hydroxy-3-trifluor HFIP (1.0 2a	mol %), [Cu] (3 equiv) omethylpyridine (20 mol %) mL), 90 °C, 18 h. EtO ₂ C	$ \begin{array}{c} $
entry	[Cu]	3a ⁸ yield (%) ^a	Ratio (p:others) ^a
1	Cu(TFA) ₂	21	7:1
2	$CuCl_2$	-	-
3	CuI	11	5:1
4	$Cu(OAc)_2$	40	8:1

Table S6: Optimization by Varying Different Cu Salts

Reaction condition: **1a**₈ (0.1 mmol), **2a** (2 equiv), Pd(OAc)₂ (10 mol %), [Cu] (3 equiv), 2-hydroxy-3-trifluoromethylpyridine (20 mol %), HFIP (1.0 mL), 90 °C, 18 h. ^{*a*}Yield and selectivity are based on ¹H NMR of the crude reaction mixture using CH₂Br₂ as internal standard; products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers.

	Pd(OAc) ₂ (10 mol % DT + CO₂Et 2,6-di- <i>tert</i> -butyl-4-me AcOH (2 equiv.), HF 2a	6), Cu(OAc) ₂ (3 equiv) thylpyridine (20 mol %) IP (1.5 mL), T °C, 48 h. EtO ₂ C	$\begin{array}{c} O \\ O \\ O \\ O \\ D \\ \end{array} \\ D \\ C \\ C \\ C \\ C \\ N \\ = D \\ \end{array}$
entry	Temperature (°C)	3as yield (%) ^a	Ratio (p:others) ^a
1	70	72	12:1
2	80	53	12:1
3	90	29	13:1
4	60	68	12:1
5	65	72	11:1
6	75	$80 (72)^b$	12:1

Table S7: Optimization of Reaction Temperature

Reaction condition: **1a**₈ (0.1 mmol), **2a** (3 equiv), Pd(OAc)₂ (10 mol %), Cu(OAc)₂ (0.5 equiv), 2,6-di-tert-butyl-4-methylpyridine (20 mol %), AcOH (2 equiv), HFIP (1.5 mL), T °C, 48 h. ^{*a*}Yield and selectivity are based on ¹H NMR of the crude reaction mixture using CH₂Br₂ as internal standard; products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers. ^{*b*}Isolated yield.

$H = \frac{1}{p} \frac{1}{m} \frac{1}{1a_8}$	DT + CO ₂ Et 2a Pd(OAc) ₂ (10 mol 2,6-di- <i>tert</i> -butyl-4-m Acid (2 equiv), HFII	%), Cu(OAc) ₂ (3 equiv) hethylpyridine (20 mol %) P (1.5 mL), 75 °C, 48 h. EtO ₂ C	$\begin{array}{c} O \\ O \\ B \\$
entry	Acid (2 equiv.)	3as yield (%) ^{<i>a</i>}	Ratio $(p:others)^a$
1	TFA	-	-
2	ОН	-	-
3		-	-
4	Соон	74	11:1
5	НСООН	70	10:1
6	о	63	12:1
7	осон	68	12:1
8	ОН	64	12:1

Table S8: Optimization by Varying Different Acids

Reaction condition: **1a**₈ (0.1 mmol), **2a** (3 equiv), Pd(OAc)₂ (10 mol %), Cu(OAc)₂ (0.5 equiv), 2,6-di-tert-butyl-4-methylpyridine (20 mol %), Acid (2 equiv), HFIP (1.5 mL), T °C, 48 h. ^{*a*}Yield and selectivity are based on ¹H NMR of the crude reaction mixture using CH₂Br₂ as internal standard; products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers.

2.5 General Procedures and Characterizations of Products



General Procedure A

An oven-dried Schlenk tube (50 mL) was charged with a magnetic stir bar, under air or O₂ atmosphere, **1** (0.1 mmol, 1.0 equiv), **2** (0.3 mmol, 3.0 equiv), Pd(OAc)₂ (2.2 mg, 0.01 mmol, 10 mol %), Cu(OAc)₂ (9.1 mg, 0.05 mmol, 0.5 equiv), 2,6-di-tert-butyl-4-methylpyridine (4.1 mg, 0.02 mmol, 20 mol %), AcOH (0.2 mmol, 2.0 equiv), HFIP (1.5 mL) were added. The reaction mixture was stirred vigorously on a preheated hotplate (70 or 75 °C) for 48 h and then cooled down to room temperature. After removal of HFIP under reduced pressure, then diluted with EtOAc (10 mL) and filtered through a short pad of Celite and neutral alumina. The sealed tube and Celite and neutral alumina pad were washed with an additional 50 mL EtOAc. The filtrate was concentrated in vacuo, and crude ¹H NMR spectrum was taken using CH₂Br₂ as internal standard. Products ratios were determined from crude ¹H NMR and products of others were mainly *m*- and *o*-isomers. The resulting residue was purified by flash silica gel chromatography or preparative thin layer chromatography using petroleum ether/EtOAc (3:1-2:1) as the eluent to give the desired products. Isolated yield of pure desired *para*-isomer was reported herein.

General Procedure B

An oven-dried 15 mL sealed tube (with a Teflon cap) equipped with a magnetic stir bar was charged with compound **1** (0.1 mmol, 1.0 equiv), **2** (0.2 mmol, 2.0 equiv or 0.3 mmol, 3.0 equiv), $Pd(OAc)_2$ (2.2 mg, 0.01 mmol, 10 mol %), AgOAc (50.1 mg, 0.3 mmol, 3.0 equiv), 3-(trifluoromethyl)pyridin-2-ol (3.2 mg, 0.02 mmol, 20 mol %). HFIP (1.0 mL or 1.5 mL) were added. The reaction mixture was stirred vigorously on a preheated hotplate (80, 90 or 100 °C) for 24 h and then cooled down to room temperature. After removal of HFIP under reduced pressure, then diluted with EtOAc (10 mL) and filtered through a short pad of Celite and neutral alumina. The sealed tube and Celite and neutral alumina pad were washed with an additional 50 mL EtOAc. The filtrate was concentrated in vacuo, and crude ¹H NMR spectrum was taken using
CH_2Br_2 as internal standard. The resulting residue was purified by flash silica gel chromatography or preparative thin layer chromatography using petroleum ether/EtOAc (3:1-2:1) as the eluent to give the desired products. Isolated yield of pure desired *para*-isomer was reported herein.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)phenyl)acrylate (3a)

The general procedure **A** was followed. (75 °C under air) Conversion: 81 %. Yield: 42.3 mg (72%), *p*: others = 12:1. When the general procedure **B** was followed. [**2** (2.0 equiv), HFIP (1.5 mL), 90 °C], Conversion: 87 %. Yield: 47.0 mg (79%), *p*: others = 15:1. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.74 – 7.65 (m, 2H), 7.64 – 7.57 (m, 3H), 7.45 (t, *J* = 7.7 Hz, 2H), 7.40 – 7.36 (m, 4H), 7.34 – 7.27 (m, 3H), 7.00 (d, *J* = 7.9 Hz, 2H), 6.37 (d, *J* = 16.0 Hz, 1H), 5.13 (s, 2H), 4.26 (q, *J* = 7.1 Hz, 2H), 2.95 – 2.92 (m, 2H), 2.90 – 2.86 (m, 2H), 1.34 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.2, 167.2, 149.7, 148.7, 144.3, 142.8, 139.8, 139.6, 137.9, 136.9, 136.6, 134.0, 132.6, 129.4, 129.0, 128.9, 128.8, 128.3, 128.1, 127.8, 122.7, 117.8, 60.6, 49.3, 37.8, 30.5, 14.5. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₉CIN₂O₅SNa⁺ [M+Na⁺] 611.1378, found 611.1378.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-3-methylphenyl)acrylate (3b)

The general procedure **A** was followed. (75 °C under air) Conversion: 80 %. Yield: 45.7 mg (76%), p: others = 15:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.7, 1.9 Hz, 1H), 7.75 – 7.67 (m, 2H), 7.65 – 7.54 (m, 3H), 7.49 – 7.35 (m, 6H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.22 (s, 1H), 7.16 (d, J = 8.0 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 6.36 (d, J = 16.0 Hz, 1H), 5.15 (s, 2H), 4.25 (q, J = 7.1 Hz, 2H), 2.86 (s, 4H), 2.14 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). ¹³C

NMR (101 MHz, Chloroform-*d*) δ 172.4, 167.2, 149.6, 148.6, 144.4, 140.9, 139.8, 139.6, 137.9, 136.9, 136.7, 136.6, 134.0, 132.7, 130.0, 129.4, 129.1, 128.93, 128.91, 128.8, 128.1, 127.6, 125.9, 122.7, 117.6, 60.5, 49.4, 36.5, 27.9, 19.2, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₃H₃₁ClN₂O₅SNa⁺ [M+Na⁺] 625.1534, found 625.1534.



Ethyl (*E*)-3-(3-chloro-4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido) -3-oxopropyl)phenyl)acrylate (3c)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 80 %. Yield: 37.3 mg (60%), p: others = 7.5:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 2.0 Hz, 1H), 7.74 – 7.68 (m, 2H), 7.61 (td, J = 7.2, 2.0 Hz, 2H), 7.54 (d, J = 16.0 Hz, 1H), 7.45 (t, J = 7.8 Hz, 2H), 7.40 (s, 5H), 7.31 (dd, J = 7.6, 4.7 Hz, 1H), 7.21 (dd, J = 7.8, 1.8 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.37 (d, J = 16.0 Hz, 1H), 5.15 (s, 2H), 4.26 (q, J = 7.2 Hz, 2H), 3.00 – 2. 93 (m, 4H), 1.34 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 166.8, 149.8, 148.7, 142.8, 139. 9, 139.8, 139.6, 138. 0, 136.9, 136.6, 134.60, 134.58, 134. 0, 131.2, 129.4, 128.99, 128.97, 128. 9, 128.8, 128.2, 127.7, 126.5, 122.7, 119.4, 60.8, 49.4, 36.0, 28.7, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₈Cl₂N₂O₅SNa⁺ [M+Na⁺] 645.0988, found 645.0988.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-3-(trifluoromethoxy)phenyl)acrylate (3d)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 69 %. Yield: 34.3 mg (51%), p: others = 13:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.32 (dd, *J* = 4.8, 2.0 Hz, 1H), 7.63 (d, *J* = 7.4 Hz, 2H), 7.57 – 7.47 (m, 3H), 7.38 (t, *J* = 7.8 Hz, 2H), 7.35 – 7.31 (m, 4H), 7.23 (dd, *J* = 7.5, 4.8 Hz, 1H), 7.21 – 7.15 (m, 2H), 7.03 (d, *J* = 7.9 Hz, 1H), 6.31 (d, *J* = 16.0 Hz, 1H), 5.07 (s, 2H), 4.19 (q, *J* = 7.1 Hz, 2H), 2.86 (s, 4H), 1.27 (t, *J* = 7.1 Hz, 3H). ¹³C

NMR (101 MHz, Chloroform-*d*) δ 172.0, 166.6, 149.7, 148.7, 147.9, 142.8, 139.8, 139.5, 137.9, 136.9, 136.6, 134.7, 134.0, 131.4, 129.4, 129.0, 128.9, 128.8, 128.1, 127.6, 126.4, 122.7, 120.5 (d, $J_{C-F} = 258.2$ Hz), 119.62, 119.58, 119.56, 60.8, 49.4, 36.3, 25.1, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₃H₂₈ClF₃N₂O₆SNa⁺ [M+Na⁺] 695.1201, found 695.1200.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-3-(trifluoromethyl)phenyl)acrylate (3e)

The general procedure **B** was followed. (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 42 %. Yield: 25.0 mg (38%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 2.0 Hz, 1H), 7.71 – 7.68 (m, 3H), 7.65 – 7.57 (m, 3H), 7.51 – 7.38 (m, 7H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 5.15 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 3.06 (t, J = 7.5 Hz, 2H), 2.92 (t, J = 7.5 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 166.6, 149.7, 148.7, 142.6, 141.0 (d, $J_{C-F} = 1.1$ Hz), 139.8, 139.5, 138.0, 136.9, 136.6, 134.0, 133.2, 131.9, 131.1, 129.4, 129.3 (d, $J_{C-F} = 30.1$ Hz), 129.00, 128.99, 128.87, 128.2, 127.6, 125.8 (q, $J_{C-F} = 5.8$ Hz), 124.1 (q, $J_{C-F} = 271.4$ Hz), 122.7, 119.8, 60.9, 49.5, 37.9, 27.5, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₃H₂₈ClF₃N₂O₅SNa⁺ [M+Na⁺] 679.1252, found 679.1248.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2-methylphenyl)acrylate (3f)

The general procedure **A** was followed. (75 °C under air) Conversion: 60 %. Yield: 25.9 mg (43%), *p*: others = 7:1; (75 °C under O₂) Yield: 30.8 mg (51%), *p*: others = 8:1. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.90 (d, *J* = 15.9 Hz, 1H), 7.74 – 7.66 (m, 2H), 7.64 – 7.56 (m, 2H), 7.45 (t, *J* = 7.7 Hz, 2H), 7.41 – 7.36 (m, 5H), 7.30 (dd, *J* = 7.6, 4.8 Hz, 1H), 6.84 – 6.81 (m, 2H), 6.30 (d, *J* = 15.9 Hz, 1H),

5.14 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 2.92 (t, J = 7.5 Hz, 2H), 2.84 (t, J = 7.5 Hz, 2H), 2.33 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.3, 167.2, 149.7, 148.7, 142.4, 142.0, 139.8, 139.6, 137.92, 137.89, 137.0, 136.6, 133.9, 131.6, 130.9, 129.4, 129.0, 128.9, 128.8, 128.1, 127.7, 126.7, 126.4, 122.7, 118.8, 60.6, 49.3, 37.8, 30.4, 19.9, 14.5. HRMS (m/z, ESI-TOF): Calcd for C₃₃H₃₁ClN₂O₅SNa⁺ [M+Na⁺] 625.1534, found 625.1533.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2-methoxyphenyl)acrylate (3g)

The general procedure **A** was followed. (75 °C under air) Conversion: 72 %. Yield: 37.1 mg (60%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.91 (d, J = 16.2 Hz, 1H), 7.75 – 7.66 (m, 2H), 7.64 – 7.56 (m, 2H), 7.51 – 7.34 (m, 6H), 7.30 (m, 2H), 6.61 (s, 1H), 6.56 (d, J = 7.9 Hz, 1H), 6.47 (d, J = 16.1 Hz, 1H), 5.14 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.97 – 2.93 (m, 2H), 2.92 – 2.86 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.2, 167.7, 158.4, 149.6, 148.6, 144.4, 139.8, 139.7, 139.6, 137.9, 136.9, 136.5, 133.9, 129.3, 129.2, 128.9, 128.8, 128.0, 127.6, 122.7, 121.6, 120.5, 118.3, 111.4, 60.4, 55.5, 49.3, 37.8, 30.9, 14.5. HRMS (m/z, ESI-TOF): Calcd for C₃₃H₃₁ClN₂O₆SNa⁺ [M+Na⁺] 641.1484, found 641.1484.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2-fluorophenyl)acrylate (3h)

The general procedure **A** was followed (75 °C under air). Conversion: 85 %. Yield: 48.5 mg (80%), *p*: others > 20:1. The general procedure **B** was followed. (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Yield: 43.6 mg (72%), *p*: others = 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, *J* = 4.8, 2.0 Hz, 1H), 7.75 – 7.65 (m, 3H), 7.60 (td, *J* = 7.6, 1.7 Hz, 2H), 7.45 (t, *J* = 7.7 Hz, 2H), 7.42 – 7.34 (m, 4H), 7.34

-7.27 (m, 2H), 6.78 (dd, J = 7.9, 1.7 Hz, 1H), 6.68 (dd, J = 11.5, 1.7 Hz, 1H), 6.45 (d, J = 16.1 Hz, 1H), 5.13 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 2.95 - 2.90 (m, 2H), 2.88 - 2.84 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-d) δ 171.9, 167.0, 161.2 (d, $J_{C-F} = 254.3$ Hz), 149.6, 148.6, 145.0 (d, $J_{C-F} = 8.2$ Hz), 139.7, 139.5, 137.9, 137.0 (d, $J_{C-F} = 2.6$ Hz), 136.8, 136.6, 134.0, 129.4, 129.1 (d, $J_{C-F} = 3.6$ Hz), 129.01, 128.96, 128.8, 128.1, 127.6, 124.6 (d, $J_{C-F} = 3.1$ Hz), 122.7, 120.5 (d, $J_{C-F} = 11.9$ Hz), 120.3 (d, $J_{C-F} = 6.6$ Hz), 116.0 (d, $J_{C-F} = 21.9$ Hz), 60.7, 49.3, 37.4, 30.2, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₈ClFN₂O₅SNa⁺ [M+Na⁺] 629.1284, found 629.1280.



Ethyl (*E*)-3-(2-chloro-4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamid o)-3-oxopropyl)phenyl)acrylate (3i)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 75 %. Yield: 37.3 mg (60%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 8.00 (d, J = 16.0 Hz, 1H), 7.68 (d, J = 7.5 Hz, 2H), 7.64 – 7.57 (m, 2H), 7.45 (t, J = 7.8 Hz, 2H), 7.42 – 7.37 (m, 5H), 7.34 – 7.28 (m, 1H), 7.02 (s, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.36 (d, J = 16.0 Hz, 1H), 5.14 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 2.93 (t, J = 6.9 Hz, 2H), 2.85 (t, J = 6.9 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 166.7, 149.7, 148.7, 144.0, 140.1, 139.8, 139.5, 137.9, 136.9, 136.6, 135.0, 134.1, 130.7, 129.9, 129.4, 129.1, 129.0, 128.9, 128.2, 127.7, 127.6, 127.4, 122.7, 120.5, 60.8, 49.3, 37.5, 30.1, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₈Cl₂N₂O₅SNa⁺ [M+Na⁺] 645.0988, found 645.0988.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2-(trifluoromethoxy)phenyl)acrylate (3j)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 60 %. Yield: 33.6 mg (50%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (d, J = 3.6 Hz, 1H), 7.83 (d, J = 16.1 Hz, 1H), 7.71 – 7.66 (m, 2H), 7.65 – 7.56 (m, 2H), 7.51 – 7.37 (m, 7H), 7.31 (dd, J = 7.6, 4.7 Hz, 1H), 7.00 – 6.88 (m, 2H), 6.41 (d, J = 16.1 Hz, 1H), 5.14 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 2.96 – 2.87 (m, 4H), 1.34 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 166.6, 149.7, 148.7, 147.5 (d, J = 1.5 Hz), 144.6, 139.8, 139.5, 138.0, 137.1, 136.9, 136.6, 134.1, 129.4, 129.1, 129.0, 128.9, 128.2, 128.1, 127.6, 127.3, 125.9, 122.7, 121.4, 120.8, 120.5 (q, J = 258.7 Hz), 60.8, 49.4, 37.6, 30.3, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₃H₂₈ClF₃N₂O₆SNa⁺ [M+Na⁺] 695.1201, found 695.1201.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-3,5-dimethylphenyl)acrylate (3k)

The general procedure **A** was followed (75 °C under O₂). Conversion: 65 %. Yield: 35.1 mg (57%), *p*: others = 8:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.73 (dd, *J* = 7.3, 1.7 Hz, 2H), 7.65 – 7.59 (m, 2H), 7.56 (d, *J* = 16.0 Hz, 1H), 7.49 – 7.40 (m, 6H), 7.31 (dd, *J* = 7.5, 4.8 Hz, 1H), 7.10 (s, 2H), 6.36 (d, *J* = 16.0 Hz, 1H), 5.18 (s, 2H), 4.24 (q, *J* = 7.1 Hz, 2H), 2.91 – 2.82 (m, 2H), 2.69 – 2.65 (m, 2H), 2.11 (s, 6H), 1.32 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.6, 167.3, 149.7, 148.7, 144.5, 139.8, 139.6, 139.5, 138.0, 137.0, 136.9, 136.6, 134.0, 132.4, 129.4, 129.00, 128.96, 128.8, 128.0, 127.7, 122.7, 117.6, 60.5, 49.5, 35.3, 25.0, 19.7, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₄H₃₃ClN₂O₅SNa⁺ [M+Na⁺] 639.1691, found 639.1688.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2-fluoro-3-methylphenyl)acrylate (3l)

The general procedure A was followed (75 °C under air). Conversion: 85 %. Yield: 43.4

mg (70%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.74 (d, *J* = 16.2 Hz, 1H), 7.70 – 7.66 (m, 2H), 7.64 – 7.56 (m, 2H), 7.47 – 7.39 (m, 6H), 7.31 (dd, *J* = 7.5, 4.7 Hz, 1H), 7.15 (t, *J* = 7.7 Hz, 1H), 6.70 (d, *J* = 8.0 Hz, 1H), 6.44 (d, *J* = 16.1 Hz, 1H), 5.15 (s, 2H), 4.26 (q, *J* = 7.1 Hz, 2H), 2.86 (s, 4H), 2.02 (d, *J* = 2.4 Hz, 3H), 1.33 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 167.1, 159.7 (d, *J*_{C-F} = 252.0 Hz), 149.6, 148.7, 143.1 (d, *J*_{C-F} = 4.6 Hz), 139.8, 139.5, 137.9, 137.6 (d, *J*_{C-F} = 3.6 Hz), 136.9, 136.5, 134.0, 129.4, 128.98, 128.97, 128.9, 128.1, 127.5, 125.8 (d, *J*_{C-F} = Hz), 124.4 (d, *J*_{C-F} = 3.7 Hz), 124.0 (d, *J*_{C-F} = 16.6 Hz), 122.7, 120.4 (d, *J*_{C-F} = 13.5 Hz), 120.0 (d, *J*_{C-F} = 6.4 Hz), 60.7, 49.4, 36.5, 28.0 (d, *J*_{C-F} = 2.6 Hz), 14.4, 10.4 (d, *J*_{C-F} = 7.0 Hz). HRMS (m/z, ESI-TOF): Calcd for C₃₃H₃₀ClFN₂O₅SNa⁺ [M+Na⁺] 643.1440, found 643.1440.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2-fluoro-5-methylphenyl)acrylate (3m)

The general procedure A was followed (75 °C under air). Conversion: 80 %. Yield: 43.4 mg (70%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.38 (dd, J = 4.7, 1.9 Hz, 1H), 7.74 – 7.65 (m, 3H), 7.65 – 7.57 (m, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.42 – 7.40 (m, 4H), 7.30 (dd, J = 7.5, 4.8 Hz, 1H), 7.19 (d, J = 7.4 Hz, 1H), 6.57 (d, J = 11.4 Hz, 1H), 6.45 (d, J = 16.2 Hz, 1H), 5.16 (s, 2H), 4.25 (q, J = 7.1 Hz, 2H), 2.89 – 2.79 (m, 4H), 2.10 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.0, 167.0, 159.7 (d, $J_{C-F} = 252.0$ Hz), 149.6, 148.6, 142.8 (d, $J_{C-F} = 7.5$ Hz), 139.7, 139.5, 137.9, 137.2 (d, $J_{C-F} = 2.2$ Hz), 136. 9, 136.5, 134.1, 132.2 (d, $J_{C-F} = 3.2$ Hz), 130.5 (d, $J_{C-F} = 3.2$ Hz), 129.4, 129. 0, 128. 9, 128.1, 127.6, 122.7, 120.2 (d, $J_{C-F} = 11.8$ Hz), 120.1 (d, $J_{C-F} = 6.8$ Hz), 115.8 (d, $J_{C-F} = 22.0$ Hz), 60.6, 49.4, 36.1, 27.8, 18.6, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₃H₃₀CIFN₂O₅SNa⁺ [M+Na⁺] 643.1440, found 643.1439.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2,6-difluorophenyl)acrylate (3n)

The general procedure **A** was followed (75 °C under air). Conversion: 84 %. Yield: 45.6 mg (73%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.72 – 7.64 (m, 3H), 7.64 – 7.57 (m, 2H), 7.46 (t, J = 7.9 Hz, 2H), 7.43 – 7.37 (m, 4H), 7.30 (dd, J = 7.5, 4.8 Hz, 1H), 6.65 (d, J = 16.5 Hz, 1H), 6.53 (d, J = 9.6 Hz, 2H), 5.14 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 2.97 – 2.89 (m, 2H), 2.86 – 2.83 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.6, 167.1, 161.5 (dd, $J_{C-F} = 255.5$, 7.7 Hz), 149.6, 148.7, 145.0 (t, $J_{C-F} = 10.2$ Hz), 139.7, 139.5, 137.9, 136.8, 136.5, 134.2, 130.6, 129.5, 129.1, 129.0, 128.9, 128.2, 127.5, 123.7 (t, $J_{C-F} = 8.5$ Hz), 122.7, 111.8 (dd, $J_{C-F} = 25.4$, 14.2 Hz), 110.4 (t, $J_{C-F} = 15.2$ Hz), 60.8, 49.4, 37.1, 30.2, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₇ClF₂N₂O₅SNa⁺ [M+Na⁺] 647.1189, found 647.1186.



Ethyl (*E*)-3-(3-chloro-4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamid o)-3-oxopropyl)-2-fluorophenyl)acrylate (30)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 70 %. Yield: 35.2 mg (55%), p: others = 15:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.74 – 7.66 (m, 3H), 7.64 – 7.55 (m, 2H), 7.49 – 7.36 (m, 6H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 6.89 (dd, J = 8.1, 1.3 Hz, 1H), 6.47 (d, J = 16.2 Hz, 1H), 5.15 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 3.02 – 2.98 (m, 2H), 2.96 – 2.94 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 166.6, 156.7 (d, $J_{C-F} = 255.6$ Hz), 149.7, 148.7, 142.0, 139.8, 139.5, 137.9, 136. 9, 136.6, 136.2 (d, $J_{C-F} = 2.3$ Hz), 134.0, 129.4, 129.03, 128.97, 128.8, 128.2, 127.6, 126.4 (d, $J_{C-F} = 3.3$ Hz), 125.7 (d, $J_{C-F} = 3.8$ Hz), 122.7, 122.1 (d, $J_{C-F} = 12.3$ Hz), 121. 9 (d, $J_{C-F} = 17.8$ Hz), 121.6 (d, $J_{C-F} = 6.4$

Hz), 60.9, 49.4, 35.8, 28.7 (d, $J_{C-F} = 2.4$ Hz), 14.4. HRMS (m/z, ESI-TOF): Calcd for $C_{32}H_{27}C_{12}FN_2O_5SNa^+$ [M+Na⁺] 663.0894, found 663.0894.



Ethyl (*E*)-3-(2-chloro-4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamid o)-3-oxopropyl)-6-fluorophenyl)acrylate (3p)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 68 %. Yield: 36.5 mg (57%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.82 (d, J = 16.4 Hz, 1H), 7.71 – 7.66 (m, 2H), 7.61 (td, J = 7.7, 1.8 Hz, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.42 – 7.37 (m, 4H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 6.87 (s, 1H), 6.64 (d, J = 16.0 Hz, 1H), 6.64 (d, J = 10.6 Hz, 1H), 5.14 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 2.93 (t, J = 7.1 Hz, 2H), 2.84 (t, J = 6.6 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.6, 167.0, 161. 9 (d, $J_{C-F} = 256.7$ Hz), 149.7, 148.7, 144.3 (d, $J_{C-F} = 9.8$ Hz), 139.8, 139.5, 138. 0, 136.8, 136.6, 135.9 (d, $J_{C-F} = 6.0$ Hz), 134.6 (d, $J_{C-F} = 2.2$ Hz), 134.2, 129.5, 129.1, 129.1, 128.9, 128.2, 127.5, 125. 0 (d, $J_{C-F} = 2.9$ Hz), 124.8 (d, $J_{C-F} = 14.6$ Hz), 122.7, 119.6 (d, $J_{C-F} = 14.2$ Hz), 114.9 (d, $J_{C-F} = 23.5$ Hz), 60. 0, 49.4, 37.2, 29.9, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₇Cl₂FN₂O₅SNa⁺ [M+Na⁺] 663.0894, found 663.0888.



Ethyl (*E*)-3-(4-(4-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-4-oxo butan-2-yl)phenyl)acrylate (3q)

The general procedure A was followed (75 °C under air). Conversion: 80 %. Yield: 42.1 mg (70%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.70 – 7.64 (m, 2H), 7.64 – 7.56 (m, 3H), 7.46 (t, J = 7.9 Hz, 2H), 7.41 – 7.24 (m, 7H), 6.97 (d, J = 7.9 Hz, 2H), 6.36 (d, J = 16.0 Hz, 1H), 5.14 – 5.02 (m, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.34

(h, J = 7.0 Hz, 1H), 2.98 (dd, J = 16.7, 7.5 Hz, 1H), 2.84 (dd, J = 16.7, 6.7 Hz, 1H), 1.34 (t, J = 7.1 Hz, 3H), 1.12 (d, J = 7.0 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.7, 167.2, 149.6, 148.6, 148.0, 144.3, 139.7, 139.7, 137.8, 137.0, 136.6, 133.9, 132.6, 129.4, 129.0, 128.9, 128.8, 128.3, 128.1, 127.6, 127.4, 122.7, 117.8, 60.6, 49.1, 44.4, 36.0, 21.7, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₃H₃₁ClN₂O₅SNa⁺ [M+Na⁺] 625.1534, found 625.1534.



Ethyl (*E*)-3-(4-(1-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-1-oxo - pentan-3-yl)phenyl)acrylate (3r)

The general procedure **A** was followed (75 °C under air). Conversion: 75 %. Yield: 41.3 mg (67%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 2.0 Hz, 1H), 7.68 – 7.55 (m, 5H), 7.45 (t, J = 7.8 Hz, 2H), 7.38 – 7.25 (m, 6H), 7.20 (d, J = 7.4 Hz, 1H), 6.90 (d, J = 8.0 Hz, 2H), 6.36 (d, J = 16.0 Hz, 1H), 5.12 – 5.00 (m, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.11 – 3.04 (m, 1H), 2.98 (dd, J = 16.6, 8.4 Hz, 1H), 2.88 (dd, J = 16.6, 5.7 Hz, 1H), 1.59 – 1.52 (m, 1H), 1.48 – 1.37 (m, 1H), 1.34 (t, J = 7.1 Hz, 3H), 0.67 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 167.2, 149.7, 148.6, 146.4, 144.4, 139.74, 139.73, 137.8, 137.0, 136.6, 133.9, 132.6, 129.4, 129.0, 128.8, 128.7, 128.2, 128.08, 128.06, 127.6, 122.7, 117.7, 60.6, 49.0, 43.3, 43.0, 28.9, 14.4, 11.9. HRMS (m/z, ESI-TOF): Calcd for C₃₄H₃₃ClN₂O₅SNa⁺ [M+Na⁺] 639.1691, found 639.1692.



Ethyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido) -2-(1,3di -oxoisoindolin-2-yl)-3-oxopropyl)phenyl)acrylate (3s)

The general procedure A was followed (75 °C under air). Conversion: 50 %. Yield: 30.8 mg (42%), *p*: others = 9:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.38 (dd, *J* = 4.9, 1.9 Hz, 1H), 7.98 (dd, *J* = 7.4, 1.8 Hz, 2H), 7.70 – 7.58 (m, 6H), 7.57 – 7.48 (m, 3H), 7.38 – 7.27 (m, 7H), 7.23 (d, *J*

= 8.1 Hz, 2H), 6.31 (d, J = 16.0 Hz, 1H), 6.03 (dd, J = 11.0, 4.7 Hz, 1H), 5.02 – 4.88 (m, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.75 (dd, J = 13.9, 11.0 Hz, 1H), 3.58 (dd, J = 13.9, 4.7 Hz, 1H), 1.30 (t, J = 7.0 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-d) δ 170.0, 167.9, 167.1, 149.7, 148.6, 144.2, 139.8, 139.0, 138.5, 137.7, 136.5, 135.9, 134.3, 133.2, 131.4, 129.7, 129.5, 128.8, 128.7, 128.6, 128.4, 128.1, 127.6, 123.6, 122.7, 118.1, 60.6, 56.5, 50.0, 34.8, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₄₀H₃₂ClN₃O₇SNa⁺ [M+Na⁺] 756.1542, found 756.1540.



Methyl 2-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2-fluorobenzyl)acrylate (3ha₁)

The general procedure A was followed (75 °C under air). Conversion: 80 %. Yield: 30.9 mg (51%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.73 – 7.67 (m, 2H), 7.65 – 7.57 (m, 2H), 7.46 (t, *J* = 7.9 Hz, 2H), 7.41 (dd, *J* = 8.8, 1.6 Hz, 4H), 7.31 (dd, *J* = 7.6, 4.7 Hz, 1H), 7.00 (t, *J* = 7.8 Hz, 1H), 6.71 (dd, *J* = 7.7, 1.7 Hz, 1H), 6.63 (dd, *J* = 10.7, 1.7 Hz, 1H), 6.22 (s, 1H), 5.41 (s, 1H), 5.14 (s, 2H), 3.74 (s, 3H), 3.58 (s, 2H), 2.94 – 2.87 (m, 2H), 2.84 – 2.80 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.2, 167.3, 161.0 (d, *J*_{C-F} = 246.5 Hz), 149.7, 148.6, 141.0 (d, *J*_{C-F} = 7.4 Hz), 139.8, 139.6, 138.5, 137.9, 137.0, 136.6, 134.0, 131.3 (d, *J*_{C-F} = 4.9 Hz), 129.4, 129.01, 128.95, 128.8, 128.1, 127.6, 126.5, 124.0 (d, *J*_{C-F} = 3.2 Hz), 123.5 (d, *J*_{C-F} = 15.8 Hz), 122.7, 115.2 (d, *J*_{C-F} = 22.1 Hz), 52.1, 49.3, 37.8, 30.9 (d, *J*_{C-F} = 2.9 Hz), 30.1. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₈ClFN₂O₅SNa⁺ [M+Na⁺] 629.1284, found 629.1283.



Methyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo -propyl)-2-fluorophenyl)-2-methylacrylate (3ha₂) The general procedure A was followed (75 °C under air). Conversion: 80 %. Yield: 13.3 mg (22%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 2.0 Hz, 1H), 7.74 – 7.69 (m, 2H), 7.66 – 7.58 (m, 3H), 7.47 (t, J = 7.9 Hz, 2H), 7.43 – 7.37 (m, 4H), 7.31 (dd, J = 7.6, 4.8 Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 6.81 (dd, J = 8.0, 1.7 Hz, 1H), 6.69 (dd, J = 11.0, 1.7 Hz, 1H), 5.15 (s, 2H), 3.82 (s, 3H), 2.96 – 2.92 (m, 2H), 2.89 – 2.85 (m, 2H), 2.01 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 168.7, 160.3 (d, $J_{C-F} = 250.3$ Hz), 149.7, 148.7, 143.3 (d, $J_{C-F} = 7.9$ Hz), 139.8, 139.6, 138.0, 136.9, 136.6, 134.1, 131.5 (d, $J_{C-F} = 3.4$ Hz), 130.5 (d, $J_{C-F} = 3.3$ Hz), 130.4, 129.4, 129.1, 129.0, 128.9, 128.2, 127.7, 123.9 (d, $J_{C-F} = 3.1$ Hz), 122.7, 121.7 (d, $J_{C-F} = 13.8$ Hz), 115.5 (d, $J_{C-F} = 22.0$ Hz), 52.3, 49.4, 37.6, 30.2, 14.5. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₈ClFN₂O₅SNa⁺ [M+Na⁺] 629.1284, found 629.1280.



Butyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo - propyl)-2-fluorophenyl)acrylate (3hb)

The general procedure A was followed (75 °C under air). Conversion: 80 %. Yield: 43.1 mg (68%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.74 – 7.65 (m, 3H), 7.64 – 7.57 (m, 2H), 7.45 (t, J = 7.8 Hz, 2H), 7.40 – 7.35 (m, 4H), 7.34 – 7.27 (m, 2H), 6.79 (dd, J = 8.1, 1.7 Hz, 1H), 6.68 (dd, J = 11.5, 1.7 Hz, 1H), 6.46 (d, J = 16.2 Hz, 1H), 5.13 (s, 2H), 4.21 (t, J = 6.7 Hz, 2H), 2.95 – 2.91 (m, 2H), 2.88 – 2.84 (m, 2H), 1.74 – 1.63 (m, 2H), 1.50 – 1.37 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 167.1, 161.2 (d, $J_{C-F} = 254.3$ Hz), 149.6, 148.6, 145.0 (d, $J_{C-F} = 8.2$ Hz), 139.8, 139.5, 137.9, 137.0 (d, $J_{C-F} = 2.5$ Hz), 136.8, 136.5, 134.0, 129.4, 129.1 (d, $J_{C-F} = 3.4$ Hz), 129.02, 128.96, 128.8, 128.1, 127.6, 124.6 (d, $J_{C-F} = 3.2$ Hz), 122.7, 120.5 (d, $J_{C-F} = 11.8$ Hz), 120.3 (d, $J_{C-F} = 6.5$ Hz), 116.0 (d, $J_{C-F} = 21.8$ Hz), 64.6, 49.3, 37.4, 30.8, 30.2, 19.3, 13.8. HRMS (m/z, ESI-TOF): Calcd for C₃₄H₃₂CIFN₂O₅SNa⁺ [M+Na⁺] 657.1597, found 657.1599.



Methyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo -propyl)-2-fluorophenyl)acrylate (3hc)

The general procedure A was followed (75 °C under air). Conversion: 87 %. Yield: 43.2 mg (73%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.72 (d, *J* = 16.2 Hz, 1H), 7.70 – 7.65 (m, 2H), 7.60 (td, *J* = 7.7, 1.6 Hz, 2H), 7.45 (t, *J* = 7.8 Hz, 2H), 7.42 – 7.35 (m, 4H), 7.33 – 7.28 (m, 2H), 6.79 (dd, *J* = 8.0, 1.7 Hz, 1H), 6.68 (dd, *J* = 11.5, 1.7 Hz, 1H), 6.46 (d, *J* = 16.2 Hz, 1H), 5.13 (s, 2H), 3.80 (s, 3H), 2.95 – 2.91 (m, 2H), 2.88 – 2.84 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 167.4, 161.2 (d, *J*_{C-F} = 254.4 Hz), 149.6, 148.7, 145.1 (d, *J*_{C-F} = 8.1 Hz), 139.7, 139.5, 137.9, 137.3 (d, *J*_{C-F} = 2.5 Hz), 136.8, 136.5, 134.0, 129.4, 129.1 (d, *J*_{C-F} = 3.4 Hz), 129.02, 128.97, 128.8, 128.1, 127.6, 124.6 (d, *J*_{C-F} = 3.2 Hz), 122.7, 120.4 (d, *J*_{C-F} = 11.7 Hz), 119.8 (d, *J*_{C-F} = 6.6 Hz), 116.0 (d, *J*_{C-F} = 21.9 Hz), 51.9, 49.3, 37.4, 30.2. HRMS (m/z, ESI-TOF): Calcd for C₃₁H₂₆CIFN₂O₅SNa⁺ [M+Na⁺] 615.1127, found 615.1128.



Phenyl (*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxo -propyl)-2-fluorophenyl)acrylate (3hd)

The general procedure A was followed (75 °C under air). Conversion: 74 %. Yield: 39.2 mg (60%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.90 (d, J = 16.2 Hz, 1H), 7.74 – 7.68 (m, 2H), 7.65 – 7.58 (m, 2H), 7.47 (t, J = 7.8 Hz, 2H), 7.44 – 7.35 (m, 7H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 7.28 – 7.22 (m, 1H), 7.20 – 7.15 (m, 2H), 6.84 (dd, J = 8.0, 1.7 Hz, 1H), 6.73 (dd, J = 11.5, 1.6 Hz, 1H), 6.67 (d, J = 16.2 Hz, 1H), 5.15 (s, 2H), 2.98 – 2.94 (m, 2H), 2.91 – 2.98 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 165.4, 161.4 (d, $J_{C-F} = 254.9$ Hz), 150.8, 149.6, 148.7, 145.6 (d, $J_{C-F} = 8.2$ Hz), 139.8, 139.5, 139.0 (d, $J_{C-F} = 2.4$ Hz), 137.9, 136.8, 136.6, 134.1, 129.6, 129.43, 129.41, 129.03, 128.99, 128.8, 128.1, 127.6, 125.9, 124.7 (d, $J_{C-F} = 3.1$ Hz),

122.7, 121.7, 120.3 (d, $J_{C-F} = 11.7$ Hz), 119.4 (d, $J_{C-F} = 6.8$ Hz), 116.1 (d, $J_{C-F} = 21.9$ Hz), 49.34, 37.40, 30.27. HRMS (m/z, ESI-TOF): Calcd for C₃₆H₂₈ClFN₂O₅SNa⁺ [M+Na⁺] 677.1284, found 677.1278.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(3-fluoro-4-(3-oxoprop-1-en-1yl)phenyl)-*N*-(phenylsulfonyl)propanamide (3he)

The general procedure A was followed (75 °C under air). Conversion: 72 %. Yield: 36.5 mg (65%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 9.69 (d, J = 7.7 Hz, 1H), 8.39 (dd, J = 4.8, 2.0 Hz, 1H), 7.71 – 7.67 (m, 2H), 7.64 – 7.58 (m, 2H), 7.56 (d, J = 16.2 Hz, 1H), 7.46 (t, J = 7.9 Hz, 2H), 7.42 – 7.34 (m, 5H), 7.31 (dd, J = 7.5, 4.8 Hz, 1H), 6.85 (dd, J = 8.0, 1.7 Hz, 1H), 6.77 – 6.67 (m, 2H), 5.14 (s, 2H), 2.98 – 2.93 (m, 2H), 2.91 – 2.87 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 193.9, 171.8, 161.2 (d, $J_{C-F} = 255.5$ Hz), 149.7, 148.7, 146.5 (d, $J_{C-F} = 8.3$ Hz), 144.7 (d, $J_{C-F} = 3.3$ Hz), 139.8, 139.5, 138.0, 136.8, 136.6, 134.1, 130.1 (d, $J_{C-F} = 5.4$ Hz), 129.4, 129.1, 129.0, 128.93 (d, $J_{C-F} = 3.0$ Hz), 128.86, 128.2, 127.6, 124.8 (d, $J_{C-F} = 3.0$ Hz), 122.7, 120.2 (d, $J_{C-F} = 11.7$ Hz), 116.2 (d, $J_{C-F} = 21.7$ Hz), 49.4, 37.4, 30.4 (d, $J_{C-F} = 1.5$ Hz). HRMS (m/z, ESI-TOF): Calcd for C₃₀H₂₄ClFN₂O₄SNa⁺ [M+Na⁺] 585.1022, found 585.1019.



(*E*)-3-(4-(3-(*N*-(3-(2-chloropyridin-3-yl)benzyl)phenylsulfonamido)-3-oxopropyl)-2-fluorophenyl)-*N*,*N*-dimethylacrylamide (3hf)

The general procedure A was followed (75 °C under air). Conversion: 80 %. Yield: 42.3 mg (70%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.38 (dd, J = 4.8, 1.9 Hz, 1H), 7.70 – 7.55 (m, 5H), 7.44 (t, J = 7.9 Hz, 2H), 7.41 – 7.34 (m, 4H), 7.32 – 7.27 (m, 2H), 6.95 (d, J = 15.6 Hz, 1H), 6.77 (dd, J = 8.0, 1.7 Hz, 1H), 6.66 (dd, J = 11.7, 1.7 Hz, 1H), 5.13 (s, 2H), 3.15 (s, 3H), 3.06 (s, 3H), 2.94 – 2.90 (m, 2H), 2.87 – 2.83 (m, 2H). ¹³C NMR

(101 MHz, Chloroform-*d*) δ 172.0, 166.8, 161.2 (d, $J_{C-F} = 253.5$ Hz), 149.6, 148.6, 144.0 (d, $J_{C-F} = 8.1$ Hz), 139.8, 139.5, 137.9, 136.9, 136.6, 135.2, 134.0, 129.8 (d, $J_{C-F} = 3.9$ Hz), 129.4, 129.01, 128.96, 128.8, 128.1, 127.6, 124.4 (d, $J_{C-F} = 3.2$ Hz), 122.7, 121.4 (d, $J_{C-F} = 11.8$ Hz), 120.0 (d, $J_{C-F} = 7.9$ Hz), 116.0 (d, $J_{C-F} = 22.1$ Hz), 49.3, 37.5, 36.0, 30.2. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₉ClFN₃O₄SNa⁺ [M+Na⁺] 628.1444, found 628.1444.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(3-fluoro-4-(3-oxopent-1-en-1yl)phenyl)-*N*-(phenylsulfonyl)propanamide (3hg)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 76 %. Yield: 36.6 mg (62%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.72 – 7.65 (m, 2H), 7.65 – 7.56 (m, 3H), 7.45 (t, J = 7.9 Hz, 2H), 7.41 – 7.37 (m, 4H), 7.36 – 7.28 (m, 2H), 6.79 (dd, J = 8.0, 1.7 Hz, 1H), 6.74 (d, J = 16.4 Hz, 1H), 6.69 (dd, J = 11.5, 1.7 Hz, 1H), 5.13 (s, 2H), 2.95 – 2.91 (m, 2H), 2.89 – 2.85 (m, 2H), 2.70 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 201.1, 171.9, 161.4 (d, $J_{C-F} = 254.1$ Hz), 149.6, 148.7, 145.2 (d, $J_{C-F} = 8.1$ Hz), 139.8, 139.5, 137.9, 136.9, 136.6, 134.5 (d, $J_{C-F} = 2.7$ Hz), 134.7, 129.4, 129.0, 129.0, 128.9, 128.8, 128.2, 127.8 (d, $J_{C-F} = 5.8$ Hz), 127.6, 124.6 (d, $J_{C-F} = 3.1$ Hz), 122.7, 120.7 (d, $J_{C-F} = 11.8$ Hz), 116.0 (d, $J_{C-F} = 22.0$ Hz), 49.3, 37.4, 34.1, 30.2, 8.3. HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₈ClFN₂O4SNa⁺ [M+Na⁺] 613.1335, found 613.1340.

(E)-N-(3-(2-chloropyridin-3-yl)benzyl)-3-(3-fluoro-4-(2-

(phenylsulfonyl)vinyl)phenyl)-N-(phenylsulfonyl)propanamide (3hh)

The general procedure A was followed (75 °C under air). Conversion: 55 %. Yield: 30.3 mg (45%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.38 (dd, J = 4.8, 1.9 Hz, 1H), 7.97 – 7.91 (m, 2H), 7.71 – 7.63 (m, 3H), 7.63 – 7.51 (m, 5H), 7.45 (t, J = 7.7 Hz, 2H), 7.38 (d, J = 5.5 Hz, 4H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.23 (t, J = 7.8 Hz, 1H), 6.94 (d, J = 15.5 Hz, 1H), 6.80 (d, J = 8.0 Hz, 1H), 6.70 (d, J = 11.6 Hz, 1H), 5.12 (s, 2H), 2.94 – 2.90 (m, 2H), 2.89 – 2.84 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 161.5 (d, $J_{C-F} = 255.8$ Hz), 149.6, 148.7, 146.4 (d, $J_{C-F} = 8.4$ Hz), 140.6, 139.7, 139.5, 137.9, 136.8, 136.5, 135.4 (d, $J_{C-F} = 1.8$ Hz), 134.1, 133.6, 130.4 (d, $J_{C-F} = 3.1$ Hz), 129.6 (d, $J_{C-F} = 8.9$ Hz), 129.5, 129.4, 129.01, 128.97, 128.8, 128.2, 127.8, 127.6, 124.8 (d, $J_{C-F} = 3.2$ Hz), 122.8, 118.6 (d, $J_{C-F} = 11.6$ Hz), 116.2 (d, $J_{C-F} = 21.7$ Hz), 49.3, 37.3, 30.2. HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₈CIFN₂O₅S₂Na⁺ [M+Na⁺] 697.1004, found 697.1005.





The general procedure A was followed (75 °C under air). Conversion: 77 %. Yield: 38.2 mg (57%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 2.0 Hz, 1H), 7.72 – 7.65 (m, 2H), 7.64 – 7.49 (m, 3H), 7.50 – 7.41 (m, 2H), 7.41 – 7.36 (m, 4H), 7.34 – 7.25 (m, 2H), 6.79 (dd, J = 8.0, 1.7 Hz, 1H), 6.68 (dd, J = 11.5, 1.7 Hz, 1H), 6.30 (t, J = 17.9 Hz, 1H), 5.13 (s, 2H), 4.17 – 4.09 (m, 4H), 2.96 – 2.90 (m, 2H), 2.90 – 2.83 (m, 2H), 1.35 (t, J = 7.1 Hz, 6H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 161.0 (d, $J_{C-F} = 254.1$ Hz), 149.6, 148.7, 145.0 (d, $J_{C-F} = 8.3$ Hz), 141.0 (dd, $J_{C-P} = 7.4, J_{C-F} = 2.8$ Hz), 139.7, 139.5, 137.9, 136.8, 136.6, 134.2, 129.4, 129.4, 129.0, 128.9, 128.8, 128.1, 127.6, 124.5 (d, $J_{C-F} = 3.1$ Hz), 122.7, 120.9 (dd, $J_{C-P} = 23.9, J_{C-F} = 11.5$ Hz), 116.5 (dd, $J_{C-P} = 190.7, J_{C-F} = 6.3$ Hz), 116.0 (d, $J_{C-F} = 21.9$ Hz), 62.0 (d, $J_{C-P} = 5.5$ Hz), 49.3, 37.4, 30.2, 16.5 (d, $J_{C-P} = 6.4$ Hz). HRMS (m/z, ESI-TOF): Calcd for C₃₃H₃₃ClFN₂O₆PSNa⁺ [M+Na⁺] 693.1362, found 693.1362.



(E)-N-(3-(2-chloropyridin-3-yl)benzyl)-N-(phenylsulfonyl)-3-(4-

(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)propanamide (4a)

The general procedure **A** was followed (70 °C under air). Conversion: 77 %. Yield: 54.2 mg (65%), *p*: others > 20:1; The general procedure **B** was followed (**2** (3.0 equiv), HFIP (1.5 mL), 80 °C). Conversion: 85 %. Yield: 60.9 mg (73%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.74 – 7.66 (m, 2H), 7.64 – 7.56 (m, 2H), 7.45 (t, J = 7.9 Hz, 2H), 7.39 (td, J = 4.8, 4.0, 1.7 Hz, 4H), 7.33 – 7.27 (m, 3H), 7.10 (dt, J = 16.3, 2.5 Hz, 1H), 7.03 (d, J = 8.1 Hz, 2H), 6.14 (dt, J = 16.2, 12.2 Hz, 1H), 5.14 (s, 2H), 2. 97 – 2. 93 (m, 2H), 2. 91 – 2.87 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.2, 149.7, 148.7, 142.8, 139.8, 139.6, 139.5 (t, $J_{C-F} = 9.7$ Hz), 137.9, 136.9, 136.6, 134. 0, 131.7, 129.4, 129.0, 128.9, 128.8, 128.3, 127.9, 127.7, 122.7, 113. 9 (t, $J_{C-F} = 23.0$ Hz), 49.3, 37.8, 30.5. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -111. 0 (q, J = 12.3, 11.5 Hz), -121.5 – -121.7 (m), -122.7 – -123.0 (m), -123.2 – -123.3 (m), -126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₄ClF₁₃N₂O₃SNa⁺ [M+Na⁺] 857.0881, found 857.0876.



(E)-N-(3-(2-chloropyridin-3-yl)benzyl)-N-(phenylsulfonyl)-3-(4-

(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)butanamide (4b)

The general procedure A was followed (70 °C under air). Conversion: 80 %. Yield: 61.9 mg (73%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, J = 4.8, 1.9 Hz, 1H), 7.70 (d, J = 7.6 Hz, 2H), 7.61 (dd, J = 7.7, 2.6 Hz, 2H), 7.48 (t, J = 7.7 Hz, 2H), 7.41 – 7.34 (m, 3H), 7.33 – 7.26 (m, 4H), 7.11 (dt, J = 16.1, 2.3 Hz, 1H), 7.03 (d, J = 8.0 Hz, 2H), 6.14 (dt, J = 16.0, 12.1 Hz, 1H), 5.15 – 5. 06 (m, 2H), 3.36 (h, J = 6.9 Hz, 1H), 3.01 (dd, J = 16.7, 7.6 Hz, 1H), 2.87 (dd, J = 16.7, 6.7 Hz, 1H), 1.14 (d, J = 6.9 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.7, 149.7, 148.7, 148.1, 139.8, 139.7, 139.5 (t, $J_{C-F} = 9.3$ Hz), 137.9, 137.0, 136.6, 133.9, 131.7, 129.4, 129.1, 128. 9, 128.8, 128.2, 127.9, 127.6, 127.5, 122.7, 113.8 (t, $J_{C-F} = 23.0$ Hz), 49.1, 44.4, 36.0, 21.7. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -110.9 (q, J = 12.7, 12.3 Hz), -121.5 – 121.7 (m), -122.8 – -122.9 (m), -123.2 – -123.3 (m), -126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₆H₂₆ClF₁₃N₂O₃SNa⁺ [M+Na⁺] 871.1031, found 871.1032.



(E)-N-(3-(2-chloropyridin-3-yl)benzyl)-N-(phenylsulfonyl)-3-(4-

(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)pentanamide (4c)

The general procedure A was followed (70 °C under air). Conversion: 82 %. Yield: 64.7 mg (75%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (d, J = 4.7 Hz, 1H), 7.67 (d, J = 8.0 Hz, 2H), 7.64 – 7.56 (m, 2H), 7.47 (t, J = 7.6 Hz, 2H), 7.39 – 7.36 (m, 2H), 7.34 – 7.20 (m, 5H), 7.10 (d, J = 16.1 Hz, 1H), 6.97 (d, J = 7.8 Hz, 2H), 6.14 (dt, J = 16.2, 12.1 Hz, 1H), 5.30 – 4.98 (m, 2H), 3.21 – 2.80 (m, 3H), 1.63 – 1.53 (m, 1H), 1.49 – 1.39 (m, 1H), 0.68 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 149.7, 148.6, 146.4, 139. 79, 139.75, 139.6 (t, $J_{C-F} = 9.2$ Hz), 137. 9, 137.0, 136.6, 133.9, 131.7, 129.4, 129.0, 128.8, 128.7, 128.2, 128.1, 127.8, 127.6, 122.7, 113.7 (t, $J_{C-F} = 22.9$ Hz), 49.1, 43.3, 43.0, 29.0, 11. 9. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.8 Hz), -110.9 (q, J = 12.9, 12.3 Hz), -121.5 – -121.7 (m), -122.8 – -122.9 (m), -123.1 – -123.2 (m), -126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₇H₂₈ClF₁₃N₂O₃SNa⁺ [M+Na⁺] 885.1194, found 885.1189.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(2-methyl-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)propanamide (4d) The general procedure **A** was followed (70 °C under air). Conversion: 70 %. Yield: 51.7 mg (61%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.71 (d, J = 7.7 Hz, 2H), 7.65 – 7.57 (m, 2H), 7.50 – 7.38 (m, 6H), 7.31 (dd, J = 7.6, 4.8 Hz, 1H), 7.18 (s, 1H), 7.15 – 7.04 (m, 2H), 6.93 (d, J = 7.8 Hz, 1H), 6.13 (dt, J = 16.4, 12.2 Hz, 1H), 5.16 (s, 2H), 2.88 (s, 4H), 2.16 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.4, 149.7, 148.7, 140.9, 139.8, 139.6, 139.6 (t, $J_{C-F} = 8.9$ Hz), 138. 0, 137. 0, 136.9, 136.6, 134. 0, 131.8, 129.6, 129.4, 129.2, 129. 0, 128. 9, 128.2, 127.7, 125.5, 122.7, 113.6 (t, $J_{C-F} = 22.9$ Hz), 49.4, 36.5, 27.9, 19.2. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, the set of the se

J = 10.0 Hz), -110.9 (q, J = 12.7, 12.3 Hz), -121.5 - -121.7 (m), -122.8 - -122.9 (m), -123.2 - -123.3 (m), -126.1 - -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₆H₂₆ClF₁₃N₂O₃SNa⁺ [M+Na⁺] 871.1037, found 871.1032.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(2-methoxy-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)propanamide (4e)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.5 mL), 80 °C). Conversion: 70 %. Yield: 44.9 mg (52%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.7, 1.9 Hz, 1H), 7.73 (d, J = 7.8 Hz, 2H), 7.65 – 7.54 (m, 2H), 7.46 (d, J = 7.7 Hz, 2H), 7.40 (s, 4H), 7.30 (dd, J = 7.6, 4.7 Hz, 1H), 7.10 (dt, J = 16.0 Hz, 2.3 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 6.91 (d, J = 7.6 Hz, 1H), 6.82 (s, 1H), 6.13 (dt, J = 16.0, 12.1 Hz, 1H), 5.15 (s, 2H), 3.72 (s, 3H), 2. 92 – 2.85 (m, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.8, 157.8, 149.7, 148.7, 139.8 (t, $J_{C-F} = 9.2$ Hz), 139.8, 139.7, 137.9, 137.1, 136.6, 133.8, 133.2, 131.2, 130.7, 129.2, 128.88, 128.87, 128.8, 128.0, 127.8, 122.7, 120.4, 113.8 (t, $J_{C-F} = 23.3$ Hz), 108. 9, 55.3, 49.4, 36.0, 26.0. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 10.0 Hz), -110. 9 (t, J = 13.0 Hz), -121.5 – -121.7 (m), -122.8 – -122.9 (m), -123.1 – -123.2 (m), -126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₆H₂₆ClF₁₃N₂O₄SNa⁺ [M+Na⁺] 887.0986, found 887.0978.



(*E*)-3-(2-chloro-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)propanamide (4f)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.5 mL), 80 °C). Conversion: 60 %. Yield: 46.0 mg (53%), p: others = 13:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.71 (d, *J* = 7.9 Hz, 2H), 7.65 – 7.56 (m, 2H), 7.48 – 7.35 (m, 7H), 7.31 (dd, *J* = 7.6, 4.8 Hz, 1H), 7.17 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.12 (d, *J* = 8.0 Hz, 1H), 7.05 (d, *J* = 16.1 Hz, 1H), 6.16 (dt, *J* = 16.3, 11.9 Hz, 1H), 5.15 (s, 2H), 3. 02 – 2. 94 (m, 4H). ¹³C NMR (101 MHz,

Chloroform-*d*) δ 172.1, 149.7, 148.7, 139.9, 139.8, 139.6, 138.2 (t, $J_{C-F} = 9.3$ Hz), 138.0, 136.9, 136.6, 134.7, 134. 0, 133.6, 131.3, 129.4, 128.99, 128.96, 128.9, 128.5, 128.2, 127.7, 126.2, 122.7, 115.4 (t, $J_{C-F} = 23.2$ Hz), 49.4, 36.0, 28.7. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 10.0 Hz), -111.3 (t, J = 12.5 Hz), -121.5 - -121.7 (m), -122.8 - -122.9 (m), -123.1 - -123.2 (m), -126.1 - -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₃Cl₂F₁₃N₂O₃SNa⁺ [M+Na⁺] 891.0491, found 891.0484.



(*E*)-3-(3-chloro-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)propanamide (4g)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.5 mL), 80 °C). Conversion: 65 %. Yield: 48.6 mg (56%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.7, 1.7 Hz, 1H), 7.69 (d, J = 7.4 Hz, 2H), 7.66 – 7.56 (m, 2H), 7.52 (d, J = 16.2 Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 7.43 – 7.34 (m, 5H), 7.31 (dd, J = 7.5, 4.7 Hz, 1H), 7.04 (s, 1H), 6.96 (d, J = 8.9 Hz, 1H), 6.15 (dt, J = 16.3, 12.0 Hz, 1H), 5.14 (s, 2H), 2.94 (t, J = 6.5 Hz, 3H), 2.87 (t, J = 6.8 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 149.7, 148.7, 144.2, 139.8, 139.5, 138.0, 136. 9, 136.6, 135.9 (t, $J_{C-F} = 9.5$ Hz), 134.5, 134.1, 129.9, 129.4, 129.1, 129.0, 128. 9, 128.2, 127.61, 127.58, 127.5, 122.7, 116.6 (t, $J_{C-F} = 22.9$ Hz), 49.4, 37.5, 30.0. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -111.2 – -111.3 (m), -121.5 – -121.7 (m), -122.8 – -122.9 (m), -123.1 – -123.2 (m), -126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₃Cl₂F₁₃N₂O₃SNa⁺ [M+Na⁺] 891.0491, found 891.0495.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(3-fluoro-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)propanamide (4h)

The general procedure A was followed (70 °C under air). Conversion: 69 %. Yield: 51.1 mg (60%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.70 (d, *J* = 7.5 Hz, 2H), 7.66 – 7.57 (m, 2H), 7.47 (t, *J* = 7.8 Hz, 2H), 7.44 – 7.37 (m, 4H), 7.35 – 7.25

(m, 2H), 7.21 (dt, J = 16.4, 2.5 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.73 (d, J = 11.6 Hz, 1H), 6.28 (dt, J = 16.4, 12.1 Hz, 1H), 5.15 (s, 2H), 2. 98 – 2. 94 (m, 2H), 2. 91 – 2. 87 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.9, 161.0 (d, $J_{C-F} = 254.2$ Hz), 149.7, 148.7, 145.1 (d, $J_{C-F} = 8.2$ Hz), 139.8, 139.6, 138.0, 136.9, 136.6, 134.1, 132.6 (td, $J_{C-F} = 10.2$, 2.2 Hz), 129.4, 129.1, 129.06 (d, $J_{C-F} = 3.5$ Hz), 129.00, 128.86, 128.2, 127.6, 124.7 (d, $J_{C-F} = 3.2$ Hz), 122.7, 119.6 (d, $J_{C-F} = 11.7$ Hz), 116.5 (td, $J_{C-F} = 23.3$, 22.8, 7.1 Hz), 116.1 (d, $J_{C-F} = 22.0$ Hz), 49.4, 37.5, 30.2. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -111.5 (q, J = 12.7, 12.3 Hz), -115.1 (dd, J = 11.5, 7.7 Hz), -121.5 – -121.6 (m), -122.8 – -122.9 (m), -123.1 – -123.2 (m), -126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₃ClF₁₄N₂O₃SNa⁺ [M+Na⁺] 875.0787, found 875.0777.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(2,6-dimethyl-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)propanamide (4i)

The general procedure A was followed (70 °C under air). Conversion: 60 %. Yield: 38.8 mg (45%), *p*: others = 13:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, J = 4.8, 1.9 Hz, 1H), 7.74 (d, J = 7.4 Hz, 2H), 7.67 – 7.57 (m, 2H), 7.52 – 7.38 (m, 6H), 7.32 (dd, J = 7.5, 4.8 Hz, 1H), 7.06 – 7.02 (m, 3H), 6.13 (dt, J = 16.3, 12.2 Hz, 1H), 5.19 (s, 2H), 2.93 – 2.84 (m, 2H), 2.73 – 2.65 (m, 2H), 2.13 (s, 6H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.6, 149.7, 148.7, 139.8, 139.61, 139.60 (d, $J_{C-F} = 9.4$ Hz), 139.5, 138.1, 137.1, 137.0, 136.6, 134.0, 131.5, 129.4, 129.02, 128.97, 128.9, 128.1, 127.7, 127.6, 122.7, 113.6 (t, $J_{C-F} = 23.0$ Hz), 49.5, 35.4, 24.9, 19.7. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 10.0 Hz), -110.9 (q, J = 13.0 Hz), -121.5 – -121.7 (m), -122.8 – -122.9 (m), -123.2 – -123.3 (m), -126.1 – 126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₇H₂₈ClF₁₃N₂O₃SNa⁺ [M+Na⁺] 885.1194, found 885.1183.



(E)-N-(3-(2-chloropyridin-3-yl)benzyl)-3-(3-fluoro-2-methyl-4-

(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)propanamide (4j)

The general procedure A was followed (70 °C under air). Conversion: 56 %. Yield: 44.2 mg (51%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.69 (d, J = 7.2 Hz, 2H), 7.65 – 7.56 (m, 2H), 7.44 (dd, J = 16.2, 8.4 Hz, 6H), 7.31 (dd, J = 7.6, 4.8 Hz, 1H), 7.22 (dt, J = 16.3, 2.5 Hz, 1H), 7.11 (t, J = 7.7 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 6.26 (dt, J = 16.4, 12.1 Hz, 1H), 5.16 (s, 2H), 2.93 – 2.82 (m, 4H), 2.04 (d, J = 2.3 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.1, 159.5 (d, $J_{C-F} = 251.2$ Hz), 149.7, 148.7, 143.2 (d, $J_{C-F} = 4.8$ Hz), 139.8, 139.6, 138.0, 136.9, 136.6, 134.0, 133.3 – 132.9 (m), 129.4, 129.1, 129.0, 128.9, 128.2, 127.6, 125.8, 124.5 (d, $J_{C-F} = 3.5$ Hz), 124.2 (d, $J_{C-F} = 16.6$ Hz), 122.8, 119.5 (d, $J_{C-F} = 13.9$ Hz), 116.5 (td, $J_{C-F} = 24.1$, 23.7, 8.0 Hz), 49.4, 36.6, 28.0 (d, $J_{C-F} = 2.6$ Hz), 10.4 (d, $J_{C-F} = 7.0$ Hz). ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -111.4 (q, J = 12.7 Hz), -117.8 (d, J = 7.2 Hz), -121.5 – -121.7 (m), -122.8 – -122.9 (m), -123.2 – -123.3 (m), -126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₆H₂₅ClF₁₄N₂O₃SNa⁺ [M+Na⁺] 889.0943, found 889.0931.

CI N Me (CF₂)₅CF₃

(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(5-fluoro-2-methyl-4-(3,3,4,4,5,5,6,6,7,7 ,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)-propanamide (4k) The general procedure A was followed (70 °C under air). Conversion: 60 %. Yield: 50.2 mg (58%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.71 (d, J = 8.4 Hz, 2H), 7.65 – 7.57 (m, 2H), 7.47 (t, J = 7.8 Hz, 2H), 7.44 – 7.40 (m, 4H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.21 – 7.12 (m, 2H), 6.61 (d, J = 11.5 Hz, 1H), 6.26 (dt, J = 16.4, 12.1 Hz, 1H), 5.17 (s, 2H), 2.92 – 2.86 (m, 2H), 2.86 – 2.80 (m, 2H), 2.13 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.0, 159.5 (d, $J_{C-F} = 251.1$ Hz), 149.7, 148.7, 142.9 (d, $J_{C-F} = 7.7$ Hz), 139.8, 139.6, 138.0, 136.9, 136.6, 134.1, 132.7 (t, $J_{C-F} = 10.2$ Hz), 132.4 (d, $J_{C-F} = 3.3$ Hz), 130.4, 129.5, 129.1, 129.0, 128.9, 128.2, 127.6, 122.7, 119.2 (d, $J_{C-F} = 11.5$ Hz), 116.6 – 115.9 (m), 115.9 (d, $J_{C-F} = 21.9$ Hz), 49.4, 36.2, 27.9, 18.6. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -111.5 (q, J = 12.6, 12.1

Hz), -119.5 (dd, J = 11.4, 7.6 Hz), -121.5 - -121.6 (m), -122.8 - -122.9 (m), -123.2 - -123.3 (m), -126.1 - -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₆H₂₅ClF₁₄N₂O₃SNa⁺ [M+Na⁺] 889.0943, found 889.0937.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(3,5-difluoro-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)propanamide (4l)

The general procedure A was followed (70 °C under air). Conversion: 65 %. Yield: 53.1 mg (61%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.9, 1.9 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.66 – 7.58 (m, 2H), 7.47 (t, J = 7.7 Hz, 2H), 7.43 (s, 1H), 7.40 (s, 3H), 7.31 (dd, J = 7.6, 4.8 Hz, 1H), 7.16 (dd, J = 16.5, 2.7 Hz, 1H), 6.57 (d, J = 9.7 Hz, 2H), 6.52 – 6.45 (m, 1H), 5.15 (s, 2H), 2.94 (t, J = 6.6 Hz, 2H), 2.87 (t, J = 6.6 Hz, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.6, 161.2 (dd, $J_{C-F} = 254.8$, 7.4 Hz), 149.7, 148.7, 145.3 (t, $J_{C-F} = 10.3$ Hz), 139.8, 139.5, 138.0, 136.8, 136.6, 134.2, 129.5, 129.2, 129.0, 128. 9, 128.2, 127.6, 126.35 – 126.04 (m), 122.7, 120.4 – 119.4 (m), 111. 9 (dd, $J_{C-F} = 24.4$, 14.3 Hz), 109.4 (t, $J_{C-F} = 14.8$ Hz), 49.4, 37.2, 30.3. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -111.4 (d, J = 9.8 Hz), -112.3 (q, J = 12.8 Hz), -121.5 – -121.7 (m), -122.8 – -122.9 (m), -123.2 – -123.3 (m), -126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₂ClF₁₅N₂O₃SNa⁺ [M+Na⁺] 893.0692, found 893.0688.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(4-(3,3,4,4,5,5,6,6,6-nonafluorohex-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)pentanamide (4m)

The general procedure A was followed (70 °C under air). Conversion: 66 %. Yield: 38.1 mg (50%), p: others = 11:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, J = 4.8, 2.0 Hz, 1H), 7.70 – 7.57 (m, 4H), 7.47 (t, J = 7.8 Hz, 2H), 7.40 – 7.35 (m, 2H), 7.34 – 7.28 (m, 2H), 7.27 – 7.22 (m, 3H), 7.10 (dt, J = 16.2, 2.5 Hz, 1H), 6.96 (d, J = 8.0 Hz, 2H), 6.13 (dt, J = 16.3, 12.3

Hz, 1H), 5.15 - 5.01 (m, 2H), 3.13 - 3.06 (m, 1H), 3.05 - 2.85 (m, 2H), 1.61 - 1.52 (m, 1H), 1.47 - 1.40 (m, 1H), 0.68 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, Chloroformd) δ 171.8, 149.7, 148.7, 146.4, 139.79, 139.77, 139.72 - 139.46 (m), 137. 9, 137.0, 136.6, 133.9, 131.7, 129.4, 129.1, 128. 9, 128.8, 128.2, 128.1, 127.8, 127.6, 122.7, 113.6 (t, $J_{C-F} = 23.1$ Hz), 49.1, 43.3, 43.0, 29.0, 11. 9. ¹⁹F NMR (376 MHz, Chloroformd) δ -79.6 - -82.8 (m), -111.1 (q, J = 12.4 Hz), -124.0 - -124.1 (m), -125.6 - -125.7 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₈ClF₉N₂O₃SNa⁺ [M+Na⁺] 785.1258, found 785.1252.



(*E*)-3-(4-(4-bromo-3,3,4,4-tetrafluorobut-1-en-1-yl)phenyl)-*N*-(3-(2chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)pentanamide (4n)

The general procedure **A** was followed (70 °C under air). Conversion: 70 %. Yield: 35.4 mg (49%), *p*: others = 9:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, J = 4.8, 2.0 Hz, 1H), 7.72 – 7.56 (m, 4H), 7.47 (t, J = 7.6 Hz, 2H), 7.42 – 7.28 (m, 4H), 7.29 – 7.21 (m, 3H), 7.10 (d, J = 16.2 Hz, 1H), 6.95 (d, J = 8.0 Hz, 2H), 6.16 (dt, J = 16.3, 11.8 Hz, 1H), 5.18 – 4.95 (m, 2H), 3.19 – 2.77 (m, 3H), 1.62 – 1.52 (m, 1H), 1.50 – 1.36 (m, 1H), 0.68 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 149.7, 148.7, 146.3, 139. 8, 139.6 (t, $J_{C-F} = 8.9$ Hz), 137.8, 137.0, 136.6, 133.9, 131.8, 129.4, 129.0, 128. 9, 128.8, 128.2, 128.1, 127.8, 127.6, 122.7, 113.7 (t, $J_{C-F} = 23.8$ Hz), 49.1, 43.3, 43.0, 29.0, 11.9. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -65.6 (t, J = 6.5 Hz), -108.87 – -108. 9 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₃H₂₈BrClF₄N₂O₃SNa⁺ [M+Na⁺] 745.0521, found 745.0518.

(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodec-1-en-1-yl)phenyl)-*N*-(phenylsulfonyl)pentanamide (40) The general procedure **A** was followed (70 °C under air). Conversion: 70 %. Yield: 57.7 mg (60%), *p*: others > 20:1. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, J = 4.6, 1.9 Hz, 1H), 7.67 (d, J = 7.9 Hz, 2H), 7.64 – 7.57 (m, 2H), 7.47 (t, J = 7.6 Hz, 2H), 7.41 – 7.30 (m, 4H), 7.27 – 7.22 (m, 3H), 7.10 (d, J = 16.0 Hz, 1H), 6.96 (d, J = 7.9 Hz, 2H), 6.14 (dt, J = 16.2, 12.2 Hz, 1H), 5.18 – 5.02 (m, 2H), 3.18 – 2.86 (m, 3H), 1.61 – 1.53 (m, 1H), 1.51 – 1.37 (m, 1H), 0.68 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171.8, 149.7, 148.7, 146.4, 139.80, 139.76, 139.7 – 139.4 (m), 137. 9, 137.0, 136.6, 133.9, 131.7, 129.4, 129.1, 128. 9, 128.8, 128.2, 128.1, 127.8, 127.6, 122.7, 113.7 (t, J = 23.1 Hz), 49.1, 43.3, 43.0, 29.0, 11. 9. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 10.1 Hz), -110.9 (q, J = 12.9 Hz), -121.1 – -121.5 (m), -121.7 – -122.1 (m), -122.7 – -122.8 (m), -122.9 – -123.3 (m), -125.9 – -126.3 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₉H₂₈ClF₁₇N₂O₃SNa⁺ [M+Na⁺] 985.1130, found 985.1124.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3-(4-(2-(perfluorophenyl)vinyl)phenyl)-*N*-(phenylsulfonyl)pentanamide (4p)

The general procedure A was followed (70 °C under air). Conversion: 84 %. Yield: 49.0 mg (69%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.9, 1.9 Hz, 1H), 7.67 (t, J = 8.1 Hz, 2H), 7.64 – 7.58 (m, 2H), 7.48 (t, J = 7.7 Hz, 2H), 7.42 – 7.28 (m, 7H), 7.24 (d, J = 7.3 Hz, 1H), 6.95 (d, J = 7.9 Hz, 2H), 6.90 (d, J = 16.8 Hz, 1H), 5.15 – 5.01 (m, 2H), 3.19 – 2.79 (m, 3H), 1.63 – 1.52 (m, 1H), 1.51 – 1.37 (m, 1H), 0.70 (t, J = 7.4 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 171. 9, 149.7, 148.6, 145.0, 139.80, 139.77, 137.8, 137.0, 136.6, 134.6, 133. 9, 129.4, 129.0, 128. 9, 128.8, 128.11, 128.09, 127.7, 127.0, 122.7, 112.6 (td, $J_{C-F} = 13.8, 3.7$ Hz), 112.2, 49.1, 43.3, 43.1, 29.0, 11.9. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -142.4 – -143.3 (m), -156.6 (t, J = 20.8 Hz), -162.9 (td, J = 21.5, 7.8 Hz). HRMS (m/z, ESI-TOF): Calcd for C₃₇H₂₈ClF₅N₂O₃SNa⁺ [M+Na⁺] 733.1322, found 733.1321.



Ethyl (*E*)-3-(2'-((3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamoyl) -[1,1'-biphenyl]-4-yl)acrylate (6a)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 70 %. Yield: 33.7 mg (53%), p: others = 8:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.73 – 7.60 (m, 4H), 7.52 (dd, J = 7.6, 1.9 Hz, 1H), 7.46 – 7.41 (m, 3H), 7.37 – 7.34 (m, 3H), 7.34 – 7.21 (m, 6H), 7.12 (d, J = 7.6 Hz, 1H), 7.03 – 7.02 (m, 2H), 6.47 (d, J = 16.0 Hz, 1H), 4.65 (br, 2H), 4.32 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.2 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.8, 167.0, 149.6, 148.7, 143.8, 140.7, 139.71, 139.69, 138.8, 138.2, 137.7, 136.6, 136.4, 134.02, 134.00, 133.8, 129.7, 129.3, 129.0, 128.79, 128.78, 128.6, 128.5, 128.5, 128.3, 127.8, 127.7, 122.7, 119.0, 60.8, 50.6, 14.5. HRMS (m/z, ESI-TOF): Calcd for C₃₆H₂₉ClN₂O₅SNa⁺ [M+Na⁺] 659.1378, found 659.1379.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)-4'-(3,3,4,4,5,5,6,6,7,7, 8,8,8-tridecafluorooct-1-en-1-yl)-[1,1'-biphenyl]-2-carboxamide (6b)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 80 %. Yield: 52.9 mg (60%), p: others = 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.70 (d, J = 7.9 Hz, 2H), 7.60 (t, J = 7.5 Hz, 1H), 7.52 (d, J = 7.1 Hz, 1H), 7.47 – 7.40 (m, 3H), 7.38 – 7.28 (m, 7H), 7.28 – 7.22 (m, 2H), 7.21 – 7.15 (m, 1H), 7.12 (d, J = 7.7 Hz, 1H), 7.05 – 7.03 (m, 2H), 6.24 (dt, J = 16.3, 12.1 Hz, 1H), 4.68 (br, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.8, 149.6, 148.7, 140.8, 139.7, 139.4 – 139.1 (m), 138.9, 138.2, 137.7, 136.6, 136.5, 134.1, 133.8, 133.0, 130.8, 129.8, 129.4, 129.0, 128.8, 128.66, 128.65, 128.3, 128.1, 127.8, 127.8, 122.7, 115.0 (t, $J_{C-F} = 22.6$ Hz), 50.6. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.7 (t, J = 9.8 Hz), -111.0 (q, J = 12.8 Hz), -121.5 – -121.6

(m), -122.8 (br), -122. 9 – -123.0 (m), -126. 0 – -126.1 (m). HRMS (m/z, ESI-TOF): Calcd for $C_{39}H_{24}ClF_{13}N_2O_3SNa^+$ [M+Na⁺] 905.0881, found 905.0877.



(*E*)-4'-(4-bromo-3,3,4,4-tetrafluorobut-1-en-1-yl)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-*N*-(phenylsulfonyl)-[1,1'-biphenyl]-2-carboxamide (6c)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 72 %. Yield: 33.4 mg (45%), *p*: others =10:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, J = 4.8, 1.9 Hz, 1H), 7.70 (d, J = 7.8 Hz, 2H), 7.61 (t, J = 7.3 Hz, 1H), 7.52 (dd, J = 7.7, 1.9 Hz, 1H), 7.48 – 7.41 (m, 3H), 7.38 – 7.29 (m, 7H), 7.28 – 7.22 (m, 2H), 7.18 (dt, J = 16.2, 2.4 Hz, 1H), 7.12 (d, J = 7.7 Hz, 1H), 7.04 – 7.02 (m, 2H), 6.26 (dt, J = 16.1, 11.7 Hz, 1H), 4.67 (br, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.8, 149.6, 148.7, 140.6, 139.7, 139.2 (t, $J_{C-F} = 8.7$ Hz), 138.9, 138.2, 137.7, 136.6, 136.5, 134.1, 133.8, 133.1, 130.7, 129.8, 129.4, 129.0, 128.81, 128.79, 128.6, 128.2, 128.0, 127.79, 127.75, 122.7, 115.0 (t, $J_{C-F} = 24.0$ Hz), 50.6. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -65.6 (t, J = 6.4 Hz), -108. 9 – -109.0 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₅H₂₄BrClF₄N₂O₃SNa⁺ [M+Na⁺] 765.0208, found 765.0198.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-4'-(3,3,4,4,5,5,6,6,6-nonafluorohex-1-en-1yl)-*N*-(phenylsulfonyl)-[1,1'-biphenyl]-2-carboxamide (6d)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 65 %. Yield: 39.1 mg (50%), p: others = 10:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (d, *J* = 3.9 Hz, 1H), 7.70 (d, *J* = 7.9 Hz, 2H), 7.61 (t, *J* = 7.4 Hz, 1H), 7.52 (dd, *J* = 7.5, 1.9 Hz, 1H), 7.46 – 7.40 (m, 3H), 7.38 – 7.29 (m, 7H), 7.28 – 7.22 (m, 2H), 7.18 (dt, *J* = 16.1, 2.5 Hz, 1H), 7.12 (d, *J* = 7.6 Hz, 1H), 7.05 – 7.03 (m, 2H), 6.24 (dt, *J* = 16.2, 12.1 Hz, 1H), 4.66 (br, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.8, 149.6, 148.7, 140.8, 139.7, 139.2 (t, $J_{C-F} = 9.1$ Hz), 138.9, 138.2, 137.7, 136.54, 136.46, 134.1, 133.8, 133.0, 130.8, 129.8, 129.4, 129.0, 128.8, 128.7, 128.6, 128.3, 128.1, 127.81, 127.77, 122.7, 114. 9 (t, $J_{C-F} = 23.1$ Hz), 50.6. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.9 (t, J = 9.5 Hz), -111.2 (q, J = 12.3 Hz), -122.97 – -124.86 (m), -125.6 – -125.7 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₇H₂₄ClF₉N₂O₃SNa⁺ [M+Na⁺] 805.0945, found 805.0943.



Ethyl (*E*)-3-(2'-((3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamoyl)-2methyl-[1,1'-biphenyl]-4-yl)acrylate (6e)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 65 %. Yield: 33.8 mg (52%), p: others = 8:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.7, 1.9 Hz, 1H), 7.70 – 7.52 (m, 5H), 7.45 (t, J = 7.5 Hz, 1H), 7.41 – 7.26 (m, 7H), 7.21 (d, J = 7.7 Hz, 2H), 7.16 – 7.10 (m, 3H), 7.06 (d, J = 7.9 Hz, 1H), 6.47 (d, J = 16.0 Hz, 1H), 4.73 (br, 2H), 4.32 (q, J = 7.1 Hz, 2H), 2.07 (br, 3H), 1.39 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.4, 167.1, 149.6, 148.7, 144.3, 140.5, 139.78, 139.76, 138.7, 138.2, 137.7, 136.6, 136.5, 134. 9, 134.1, 133.7, 130.4, 130.3, 130.2, 128.83, 128.80, 128.76, 128.7, 128.6, 128.5, 127.7, 127.61, 127.59, 125.2, 122.7, 118.6, 60.7, 50.8, 20.2, 14.5. HRMS (m/z, ESI-TOF): Calcd for C₃₇H₃₁ClN₂O₅SNa⁺ [M+Na⁺] 673.1534, found 673.1533.



 $F_3C(F_2C)_5$

(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-2'-methyl-*N*-(phenylsulfonyl)-4'-(3,3,4,4, 5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)-[1,1'-biphenyl]-2-carboxamide (6f) The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 73 %. Yield: 49.5 mg (55%), *p*: others = 10:1. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (d, *J* = 3.7 Hz, 1H), 7.64 (d, *J* = 7.9 Hz, 2H), 7.54 (d, *J* = 7.6 Hz, 2H), 7.44 (t, *J* = 7.4 Hz, 1H), 7.40 – 7.27 (m, 6H), 7.25 – 7.18 (m, 3H), 7.17 – 7.05 (m, 5H), 6.23 (dt, J = 16.2, 12.2 Hz, 1H), 4.75 (br, 2H), 2.10 (br, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.3, 149.6, 148.7, 140.5, 139.7, 139.7 – 139.4 (m), 138.8, 138.1, 137.7, 136.6, 136.5, 134.9, 133.6, 133.0, 130.4, 130.3, 129.84, 128.80, 128.78, 128.76, 128.7, 128.6, 127.62, 127.60, 124.8, 122.7, 114.6 (t, $J_{C-F} = 22.9$ Hz), 50.8, 20.2. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.7 (t, J = 9.7 Hz), -110.9 (q, J = 13.0 Hz), -121.4 – -121.6 (m), -122.80 (br), -122. 9 – -123.1 (m), -126. 0 – -126.1 (m). HRMS (m/z, ESI-TOF): Calcd for C₄₀H₂₆ClF₁₃N₂O₃SNa⁺ [M+Na⁺] 919.1037, found 919.1027.



Ethyl (*E*)-3-(2'-((3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamoyl)-3methoxy-[1,1'-biphenyl]-4-yl)acrylate (6g)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 60 %. Yield: 35.3 mg (53%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.99 (d, *J* = 16.2 Hz, 1H), 7.69 – 7.56 (m, 3H), 7.52 (dd, *J* = 7.6, 2.0 Hz, 1H), 7.47 – 7.34 (m, 5H), 7.34 – 7.19 (m, 4H), 7.10 (dd, *J* = 7.7, 1.2 Hz, 1H), 7.02 – 7.00 (m, 2H), 6.90 (dd, *J* = 7.8, 1.6 Hz, 1H), 6.84 (s, 1H), 6.59 (d, *J* = 16.1 Hz, 1H), 4.71 (br, 2H), 4.31 (q, *J* = 7.1 Hz, 2H), 3.69 (s, 3H), 1.38 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.8, 167.6, 158.1, 149.6, 148.7, 142.1, 139.7, 139.5, 138.8, 138.5, 137.6, 136.5, 136.4, 134.0, 133.8, 130.6, 129.7, 129.3, 128.8, 128.71, 128.66, 128.6, 128.4, 128.0, 127.8, 127.5, 123.0, 122.7, 120.8, 119.4, 60.6, 55.5, 50.7, 14.5. HRMS (m/z, ESI-TOF): Calcd for C₃₇H₃₁ClN₂O₆SNa⁺ [M+Na⁺] 689.1484, found 689.1481.



(E)-N-(3-(2-chloropyridin-3-yl)benzyl)-3'-fluoro-N-(phenylsulfonyl)-4'-(3,3,4,4, 5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)-[1,1'-biphenyl]-2-carboxamide (6h) The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C).

Conversion: 70 %. Yield: 45.0 mg (50%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.41 (dd, J = 4.8, 1.9 Hz, 1H), 7.69 (d, J = 7.8 Hz, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.54 (dd, J = 7.6, 2.0 Hz, 1H), 7.50 – 7.39 (m, 3H), 7.37 – 7.24 (m, 7H), 7.14 – 7.01 (m, 5H), 6.38 (dt, J = 16.3, 11.9 Hz, 1H), 4.75 (br, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.4, 160.7 (d, $J_{C-F} = 254.6$ Hz), 149.6, 148.7, 142.8 (d, $J_{C-F} = 8.4$ Hz), 139.7, 138.8, 137.8, 137.23, 137.22, 136.43, 136.39, 134.1, 133.9, 132.4 (t, $J_{C-F} = 9.9$ Hz), 130.8, 129.7, 129.2(d, $J_{C-F} = 2.4$ Hz), 128. 9, 128.80, 128.78, 128.7, 128.2, 128.1, 127.8, 125.2 (d, $J_{C-F} = 3.1$ Hz), 122.7, 120.9 (d, $J_{C-F} = 11.4$ Hz), 117.5 (td, $J_{C-F} = 23.1$, 7.1 Hz), 116.8 (d, $J_{C-F} = 23.0$ Hz), 50.6. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -111.6 (q, J = 12.8 Hz), -113.7 – -113.8 (m), -121.5 – -121.6 (m), -122.7 – -122.8 (m), -123.0 – -123.1 (m), -128.0 – -128.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₉H₂₃ClF₁₄N₂O₃SNa⁺ [M+Na⁺] 923.0787, found 923.0784.



(*E*)-*N*-(3-(2-chloropyridin-3-yl)benzyl)-3',5'-difluoro-*N*-(phenylsulfonyl)-4'-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)-[1,1'-biphenyl]-2-

carboxamide (6i)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 55 %. Yield: 45.9 mg (50%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.40 (dd, J = 4.8, 1.9 Hz, 1H), 7.67 (d, J = 7.8 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.55 (dd, J = 7.5, 1.9 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.42 (t, J = 7.8 Hz, 2H), 7.37 – 7.27 (m, 5H), 7.22 (dt, J = 17.2, 2.6 Hz, 1H), 7.17 – 7.07 (m, 3H), 6.86 (d, J = 9.4 Hz, 2H), 6.60 (dt, J = 16.5, 11.9 Hz, 1H), 4.82 (br, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 170.1, 160.9 (dd, $J_{C-F} = 255.6$, 7.4 Hz), 149.6, 148.7, 142.8 (t, $J_{C-F} = 10.9$ Hz), 139.7, 138.8, 137.8, 136.6, 136.4, 136.2, 134.2, 134.1, 130.8, 129.6, 128.98, 128.96, 128.9, 128.7, 128.6, 128.4, 128.0, 127. 9, 126.1 (t, $J_{C-F} = 10.8$ Hz), 122.7, 112.7 (dd, $J_{C-F} = 25.6$, 14.1 Hz), 110.7 (t, $J_{C-F} = 14.8$ Hz), 50.5. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -109.9 (d, J = 9.9 Hz), -112.4 (q, J = 12.5 Hz), -121.37 – -121.74 (m), -122.7 – -122.9 (m), -123.0 – -123.1 (m), –

126.1 – -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₉H₂₂ClF₁₅N₂O₃SNa⁺ [M+Na⁺] 941.0692, found 941.0689.



Ethyl (*E*)-3-(4-((((3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamoyl)oxy) -methyl)phenyl)acrylate (6j)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 75 %. Yield: 37.2 mg (63%), p: others = 8:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.31 (dd, J = 4.9, 1.9 Hz, 1H), 7.59 – 7.51 (m, 3H), 7.49 (dd, J = 7.6, 1.9 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.38 (dt, J = 5.9, 3.1 Hz, 1H), 7.36 – 7.32 (m, 3H), 7.30 (d, J = 8.0 Hz, 2H), 7.25 – 7.17 (m, 3H), 7.02 (d, J = 7.9 Hz, 2H), 6.33 (d, J = 16.0 Hz, 1H), 5.05 (s, 2H), 5.01 (s, 2H), 4.19 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 167.0, 152.4, 149.7, 148.7, 143.8, 139.8, 139.2, 137.9, 137.2, 136.7, 136.5, 134. 9, 133.7, 129.3, 129.1, 128.83, 128.80, 128.6, 128.4, 128.3, 122.7, 119.2, 68.8, 60.8, 50.0, 14.5. HRMS (m/z, ESI-TOF): Calcd for C₃₁H₂₇ClN₂O₆SNa⁺ [M+Na⁺] 613.1171, found 613.1170.



(*E*)-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)benzyl (3-(2-chloropyri - din-3-yl)benzyl)(phenylsulfonyl)carbamate (6k)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 90 %. Yield: 66.9 mg (80%), p: others = 10:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.7, 2.0 Hz, 1H), 7.66 (d, J = 7.9 Hz, 2H), 7.58 (dd, J = 7.6, 2.0 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.49 – 7.40 (m, 4H), 7.36 – 7.28 (m, 5H), 7.17 – 7.10 (m, 3H), 6.19 (dt, J = 16.3, 12.2 Hz, 1H), 5.14 (s, 2H), 5.10 (s, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 152.3, 149.7, 148.6, 139.8, 139.2, 139.1 (t, $J_{C-F} = 9.7$ Hz), 137.9, 137.1, 136.7, 136.6, 133.8, 133.7, 129.3, 129.1, 128.9, 128.80, 128.78, 128.6, 128.4, 127.9, 122.7, 115.2 (t, $J_{C-F} = 23.0$ Hz), 68.6, 50.0. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 9.9 Hz), -111.2 (q, J = 12.9, 12.3 Hz), -121.6 – -121.7 (m), -122.8 – -122.9 (m), -123.0 – -123.2 (m), -126.0 – -126.2 (m).

HRMS (m/z, ESI-TOF): Calcd for $C_{34}H_{22}ClF_{13}N_2O_4SNa^+$ [M+Na⁺] 859.0673, found 859.0668.



Ethyl (*E*)-3-(4-((((3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamoyl)oxy) -methyl)-2-fluorophenyl)acrylate (6l)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 90 %. Yield: 45.6 mg (75%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.72 (d, *J* = 16.2 Hz, 1H), 7.66 (d, *J* = 7.7 Hz, 2H), 7.59 (dd, *J* = 7.7, 2.0 Hz, 1H), 7.54 (t, *J* = 7.1 Hz, 1H), 7.50 – 7.31 (m, 7H), 7.29 (dd, *J* = 7.6, 4.8 Hz, 1H), 6.89 (d, *J* = 8.0 Hz, 1H), 6.72 (d, *J* = 10.9 Hz, 1H), 6.50 (d, *J* = 16.2 Hz, 1H), 5.15 (s, 2H), 5.07 (s, 2H), 4.27 (q, *J* = 7.1 Hz, 2H), 1.34 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.7, 161.1 (d, *J*_{C-F} = 254.8 Hz), 152.2, 149.7, 148.6, 139.7, 139.2, 138.6 (d, *J*_{C-F} = 8.4 Hz), 137.9, 137.0, 136.51 (d, *J*_{C-F} = 11.1 Hz), 136.48, 133.8, 129.3 (d, *J*_{C-F} = 3.2 Hz), 129.2, 129.1, 128. 9, 128.8, 128.5, 128.3, 123.9 (d, *J*_{C-F} = 3.4 Hz), 122.7 (d, *J*_{C-F} = 12.0 Hz), 122.7, 121.6 (d, *J*_{C-F} = 6.6 Hz), 115.6 (d, *J*_{C-F} = 23.1 Hz), 67.8, 60.8, 50.1, 14.4. HRMS (m/z, ESI-TOF): Calcd for C₃₁H₂₆CIFN₂O₆SNa⁺ [M+Na⁺] 631.1076, found 631.1075.



(*E*)-3-fluoro-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-en-1-yl)benzyl (3-(2chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamate (6m)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 90 %. Yield: 70.9 mg (83%), p: others > 20:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (d, J = 4.5 Hz, 1H), 7.68 (d, J = 7.8 Hz, 2H), 7.60 (d, J = 7.4 Hz, 1H), 7.55 (t, J = 7.2 Hz, 1H), 7.51 – 7.41 (m, 4H), 7.40 – 7.34 (m, 3H), 7.29 (dd, J = 7.4, 4.8 Hz, 1H), 7.22 (d, J = 16.3 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.76 (d, J = 11.1 Hz, 1H), 6.33 (dt, J = 16.0, 12.0 Hz, 1H), 5.16 (s, 2H), 5.09 (s, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 160. 9 (d, $J_{C-F} = 254.3$ Hz), 152.2, 149.7, 148.7, 139.7, 139.2, 138. 9 (d, $J_{C-F} = 8.2$ Hz), 138.0, 137.1, 136.6, 133.8, 132.2 (t, $J_{C-F} = 10.1$ Hz), 129.3, 129.2, 129.1, 128.9, 128.8, 128.5, 128.4, 124.0 (d, $J_{C-F} = 3.5$ Hz), 122.7, 121.7 (d, $J_{C-F} = 11.9$ Hz), 117.8 (td, $J_{C-F} = 23.2$, 8.1 Hz), 115.7 (d, $J_{C-F} = 23.0$ Hz), 67.8 (d, $J_{C-F} = 1.5$ Hz), 50.1. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.8 (t, J = 10.0 Hz), -111.7 (q, J = 12.5, 12.0 Hz), -114.3 (dd, J = 11.0, 7.4 Hz), -121.4 - -121.7 (m), -122.7 - -123.0 (m), -123.1 - -123.2 (m), -126.1 - -126.2 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₄H₂₁ClF₁₄N₂O₄SNa⁺ [M+Na⁺] 877.0579, found 877.0576.



(E)-4-(4-bromo-3,3,4,4-tetrafluorobut-1-en-1-yl)-3-fluorobenzyl(3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamate (6n)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 84 %. Yield: 53.6 mg (75%), p: others = 10:1.

¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.7, 2.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.61 – 7.52 (m, 2H), 7.49 – 7.41 (m, 4H), 7.41 – 7.34 (m, 3H), 7.29 (dd, J = 7.5, 4.7 Hz, 1H), 7.23 (dt, J = 16.5, 2.5 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 10.9 Hz, 1H), 6.35 (dt, J = 16.2, 11.6 Hz, 1H), 5.15 (s, 2H), 5.08 (s, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 160.8 (d, $J_{C-F} = 254.2$ Hz), 152.2, 149.7, 148.6, 139.7, 139.2, 138.7 (d, $J_{C-F} = 8.2$ Hz), 137.9, 137.0, 136.6, 133.8, 132.2 (td, $J_{C-F} = 10.4$, 9.9, 2.8 Hz), 129.20, 129.15, 129.1, 128.9, 128.8, 128.5, 128.4, 123.9 (d, $J_{C-F} = 3.5$ Hz), 122.7, 121.8 (d, $J_{C-F} = 11.5$ Hz), 117.8 (td, $J_{C-F} = 23.9$, 7.2 Hz), 115.7 (d, $J_{C-F} = 23.1$ Hz), 67.8, 50.1. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -65.7 (t, J = 6.4 Hz), -109.5 (dt, J = 12.1, 6.7 Hz), -114.4 (dd, J = 11.1, 7.4 Hz). HRMS (m/z, ESI-TOF): Calcd for $C_{30}H_{21}BrClF_5N_2O4SNa^+$ [M+Na⁺] 736.9906, found 736.9905.



(E)-3-fluoro-4-(3,3,4,4,5,5,6,6,6-nonafluorohex-1-en-1-yl)benzyl(3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamate (60)

The general procedure **B** was followed (2 (3.0 equiv), HFIP (1.0 mL), 100 °C). Conversion: 84 %. Yield: 58.8 mg (78%), *p*: others = 10:1. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 7.68 (d, J = 7.9 Hz, 2H), 7.60 (dd, J = 7.5, 2.0 Hz, 1H), 7.55 (t, J = 7.4 Hz, 1H), 7.50 – 7.41 (m, 4H), 7.41 – 7.34 (m, 3H), 7.29 (dd, J = 7.5, 4.7 Hz, 1H), 7.22 (dt, J = 16.4, 2.6 Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.76 (d, J = 11.0 Hz, 1H), 6.33 (dt, J = 16.3, 12.0 Hz, 1H), 5.15 (s, 2H), 5.09 (s, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 160. 9 (d, $J_{C-F} = 254.5$ Hz), 152.2, 149.7, 148.7, 139.7, 139.2, 138. 9 (d, $J_{C-F} = 8.2$ Hz), 138.0, 137.0, 136.6, 133.8, 132.4 – 132.1 (m), 129.3(d, $J_{C-F} = 2.9$ Hz), 129.2, 129.1, 128.9, 128.8, 128.5, 128.4, 124.0 (d, $J_{C-F} = 3.4$ Hz), 122.7, 121.7 (d, $J_{C-F} = 11.9$ Hz), 117.7 (td, $J_{C-F} = 23.1$, 6.9 Hz), 115.7 (d, $J_{C-F} = 23.0$ Hz), 67.8, 50.1. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -80.5 – 81.5 (m), -112.0 (t, J = 12.1 Hz), -114.3 (dd, J = 11.1, 7.5 Hz), -124.0 (q, J = 9.4 Hz), -125.6 – -125.8 (m). HRMS (m/z, ESI-TOF): Calcd for C₃₂H₂₁ClF₁₀N₂O₄SNa⁺ [M+Na⁺] 777.0643, found 777.0635.



ethyl (*E*)-3-(2-chloro-4-((((3-(2-chloropyridin-3-yl)benzyl)(phenylsulfonyl)carbamoyl)oxy)methyl)phenyl)acrylate (6p)

The general procedure **B** was followed (2 (2.0 equiv), HFIP (1.5 mL), 90 °C). Conversion: 60 %. Yield: 33.1 mg (53%), *p*: others > 20:1.

¹H NMR (400 MHz, Chloroform-d) δ 8.39 (dd, J = 4.8, 1.9 Hz, 1H), 8.00 (d, J = 16.0 Hz, 1H), 7.65 (d, J = 7.8 Hz, 2H), 7.59 (dd, J = 7.6, 1.9 Hz, 1H), 7.54 (t, J = 7.4 Hz, 1H), 7.50 – 7.40 (m, 5H), 7.36 (t, J = 7.7 Hz, 2H), 7.29 (dd, J = 7.5, 4.7 Hz, 1H), 7.06 (s, 1H), 7.00 (d, J = 8.0 Hz, 1H), 6.40 (d, J = 16.0 Hz, 1H), 5.14 (s, 2H), 5.05 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-d) δ 166.4, 152.2, 149.7, 148.7, 139.7, 139.6, 139.2, 137.9, 137.7, 137.0, 136.6, 135.0, 133.8, 133.0, 129.6, 129.2, 129.1, 128. 9, 128.8, 128.5, 128.3, 127.8, 126.8, 122.7, 121.7, 67.8, 60.9, 50.1, 14.4. HRMS (m/z, ESI-TOF): Calcd for $C_{31}H_{27}C_{12}N_2O_6S^+$ [M+H⁺] 625.0961, found 625.0973.

2.6 Scaled-up Reactions



An oven-dried Schlenk tube (1000 mL) was charged with a magnetic stir bar, under air atmosphere, **1h** (3.0 mmol, 1.0 equiv), **2a** (9.0 mmol, 3.0 equiv), $Pd(OAc)_2$ (0.15 mmol, 5 mol %), $Cu(OAc)_2$ (1.5 mmol, 0.5 equiv), 2,6-di-tert-butyl-4-methylpyridine (0.30 mmol, 10 mol %), AcOH (6.0 mmol, 2.0 equiv), HFIP (45 mL) were added. The reaction mixture was stirred vigorously on a preheated hotplate (75 °C) for 48 h and then cooled down to room temperature. After removal of HFIP under reduced pressure, then diluted with EtOAc (200 mL) and filtered through a short pad of Celite and neutral alumina. The sealed tube and Celite and neutral alumina pad were washed with an additional 150 mL EtOAc. The resulting residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (5:1-3:1) as the eluent to give **3h**. (50 %, 0.91g)

2.7 Synthetic Applications and Hydrolysis

Synthesis of 10a:



To a solution of **3a** (0.7 mmol, 1.0 equiv) and K₂CO₃ (1.75 mmol, 2.5 equiv) in EtOH (7 mL) at room temperature stirred for 2 h. Then volatile matter was removed under reduced pressure. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (10:1-2:1) as the eluent to give **7** (yield: 95%) and **ethyl** (*E*)-**3**-(**4**-(**3**-ethoxy-**3**-oxopropyl)phenyl)acrylate (**8**). (yield: 99%) ¹H NMR (400 MHz, Chloroform-*d*) δ 7.66 (d, *J* = 16.0 Hz, 1H), 7.45 (d, *J* = 7.9 Hz, 2H),

7.22 (d, J = 7.9 Hz, 2H), 6.40 (d, J = 16.0 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 4.12 (q, J = 7.1 Hz, 2H), 2.96 (t, J = 7.7 Hz, 2H), 2.62 (t, J = 7.7 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.8, 167.3, 144.5, 143.3, 132.7, 129.0, 128.4, 117.8, 60.7, 60.6, 35.7, 30.9, 14.5, 14.3. HRMS (m/z, ESI-TOF): Calcd for C₁₆H₂₀O₄Na⁺ [M+Na⁺] 299.1254, found 299.1254.



To a solution of **8** (0.6mmol, 1.0 equiv), Pd/C (0.012 mmol, 2 mol %.), MeOH (10 mL) under H₂ atmosphere at room temperature stirred for 12 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was used in the next step without further purification.

To a solution of the residue above and LiOH·H₂O (6.0 mmol, 10 equiv) in THF:MeOH:H₂O (6:4:2 mL) at room temperature stirred for 2 h. Then volatile matter was removed under reduced pressure. Then the crude reaction mixture was extracted with EtOAc and water, The combined water phase was added 1N HCl until pH \approx 1, then filtered to give the **9a**.(yield: 99%) ¹H NMR (400 MHz, DMSO-d₆) δ 12.12 (br, 2H), 7.12 (s, 4H), 2.77 (t, J = 7.6 Hz, 4H), 2.54 – 2.47 (m, 4H). ¹³C NMR (101 MHz, DMSO-d₆) δ 173. 9, 138.5, 128.2, 35.1, 30.0. HRMS (m/z, ESI-TOF): Calcd for C12H13O4⁻ [M-H⁻] 221.0819, found 221.0819.



A suspension of 9a (44.4 mg, 0.20 mmol) in freshly distilled thionyl chloride (3 mL) was gently refluxed to complete solution of the solid (6 h). After evaporation under vacuum the residue was pumped to dryness and without further purification.
To a solution of **S2** (0.6 mmol, 3.0 equiv), triethylamine (1.2 mmol, 6.0 equiv.), DCM (10 mL) under N₂ atmosphere at room temperature stirred for 0.5 h. Then **S1** was added and stirred for another 12 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting residue was purified by preparative thin layer chromatography using EtOAc/MeOH (20:1-5:1) as the eluent to give the **10a**². (yield: 50%) ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.21 (d, *J* = 8.5 Hz, 2H), 8.09 (t, *J* = 5.6 Hz, 2H), 7.26 – 7.16 (m, 10H), 6.98 (s, 4H), 4.69 (t, *J* = 5.5 Hz, 2H), 4.48 (td, *J* = 9.0, 4.9 Hz, 2H), 3.49 (d, *J* = 5.2 Hz, 4H), 3.37 – 3.30 (m, 8H), 3.20 (p, *J* = 6.9 Hz, 4H), 2.95 (dd, *J* = 13.7, 5.0 Hz, 2H), 2.76 (dd, *J* = 13.6, 9.5 Hz, 2H), 2.62 (t, *J* = 7.9 Hz, 4H), 2.32 (t, *J* = 7.8 Hz, 4H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 171.4, 171.3, 138.7, 138.0, 129.2, 128.02, 128.00, 126.2, 72.2, 68. 9, 60.2, 54.0, 38.6, 37.9, 36.9, 30.7. HRMS (m/z, ESI-TOF): Calcd for C₃₈H₅₀N₄O₈Na⁺ [M+Na⁺] 713.3521, found 713.3521.

Synthesis of 10b:



To a solution of **3h** (1.5 mmol, 1.0 equiv) and LiOH·H₂O (15 mmol, 10 equiv) in THF:MeOH:H₂O (9:6:3 mL) at room temperature stirred for 2 h. Then volatile matter was removed under reduced pressure. Then the crude reaction mixture was extracted with EtOAc and water, The combined water phase was added 1N HCl until pH \approx 1, then filtered to give **S3**. (yield: 99%) ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.74 (t, *J* = 8.0 Hz, 1H), 7.62 (d, *J* = 16.1 Hz, 1H), 7.18 (d, *J* = 12.1 Hz, 1H), 7.13 (d, *J* = 8.1 Hz, 1H), 6.55 (d, *J* = 16.1 Hz, 1H), 2.85 (t, *J* = 7.5 Hz, 2H), 2.57 (t, *J* = 7.5 Hz, 2H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 173.6, 167.4, 160.5 (d, *J*_{C-F} = 250.7 Hz), 146.4 (d, *J*_{C-F} = 8.4 Hz), 135.8 (d, *J*_{C-F} = 3.2 Hz), 129.1 (d, *J*_{C-F} = 3.2 Hz), 125.1 (d, *J*_{C-F} = 2.9 Hz), 121.0 (d, *J*_{C-F} = 5.6 Hz), 119.6 (d, *J*_{C-F} = 11.5 Hz), 115.8 (d, *J*_{C-F} = 21.9 Hz), 34.5, 30.0. HRMS (m/z, ESI-TOF): Calcd for C₁₂H₁₀FO4⁻ [M-H⁻] 237.0569, found 237.0569.

To a solution of **S3** (1.0 mmol, 1.0 equiv), Pd/C (0.02 mmol, 2 mol %), MeOH (10 mL) under H₂ atmosphere at room temperature stirred for 12 h. Then filtered and concentrated under reduced pressure to give **9b**. (yield: 99%) ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.19 (t, *J* = 8.0 Hz, 1H), 7.02 – 6. 96 (m, 2H), 2.85 – 2.73 (m, 4H), 2.54 –

2.48 (m, 4H). ¹³C NMR (101 MHz, DMSO- d_6) δ 173.8, 173.6, 160.4 (d, J = 243.0 Hz), 141.6 (d, J = 7.6 Hz), 130.4 (d, J = 5.3 Hz), 124. 9 (d, J = 15.7 Hz), 124.2 (d, J = 2.9 Hz), 114.9 (d, J = 21.8 Hz), 35.0, 33.9, 29.8, 23.5. HRMS (m/z, ESI-TOF): Calcd for C₁₂H₁₂FO₄⁻ [M-H⁻] 239.0725, found 239.0595.



Asuspension of **9b** (48 mg, 0.20 mmol) in freshly distilled thionyl chloride (3 mL) was gently refluxed tocomplete solution of the solid (6 h). After evaporation under vacuum the residue was pumped to dryness and without further purification.

To a solution of $S2^2$ (0.6 mmol, 3.0 equiv), triethylamine (1.2 mmol, 6.0 equiv), DCM (10 mL) under N₂ atmosphere at room temperature stirred for 0.5 h. Then the S4 was added and stirred for another 12 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting residue was purified by preparative thin layer chromatography using EtOAc/MeOH (20:1-5:1) as the eluent to give the **10b**. (yield: 40%) ¹H NMR (400 MHz, DMSO- d_6) δ 8.16 (t, J = 9.2 Hz, 2H), 8.05 (t, J = 5.7 Hz, 2H), 7.26 – 7.16 (m, 10H), 7.01 (t, J = 8.0 Hz, 1H), 6.88 (d, J = 11.3 Hz, 1H), 6.82 (d, J = 7.7 Hz, 1H), 4.64 (t, J = 5.5 Hz, 2H), 4.55 - 4.50 (m, 2H), 3.52 - 4.503.45 (m, 8H), 3.41 (t, J = 5.3 Hz, 4H), 3.28 – 3.16 (m, 4H), 3.01 – 2.91 (m, 2H), 2.76 (dd, J = 13.6, 9.4 Hz, 2H), 2.66 (t, J = 7.9 Hz, 4H), 2.34 (q, J = 7.6 Hz, 4H).¹³C NMR (101 MHz, DMSO- d_6) δ 171.4, 171.2, 171.1, 160.3 (d, J_{C-F} = 242.8 Hz), 141.7 (d, J_{C-F} = 7.6 Hz), 138.00, 137.97, 130.2 (d, J_{C-F} = 5.3 Hz), 129.3, 128.1, 127.5, 126.3, 125.1 $(d, J_{C-F} = 15.9 \text{ Hz}), 124.1 (d, J_{C-F} = 3.0 \text{ Hz}), 114.7 (d, J_{C-F} = 21.9 \text{ Hz}), 114.0, 72.2, 69.0,$ 60.3, 56.2, 54.04, 54.00, 38.7, 38.0, 36.5, 35.3, 30.4, 24.0, 18.6. HRMS (m/z, ESI-TOF): Calcd for C₃₈H₄₉FN₄O₈Na⁺ [M+Na⁺] 731.3427, found 731.3426.

Synthesis of 10c:



To **31** (0.7 mmol, 1.0 equiv) and K₂CO₃ (1.75 mmol, 2.5 equiv) in EtOH (7 mL) at room temperature stirred for 2 h. Then volatile matter was removed under reduced pressure. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting residue was purified by flash silica gel chromatography using petroleum ether/EtOAc (10:1-2:1) as the eluent to give **7** (yield: 99%) and **S5** (yield: 99%). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.79 (d, *J* = 16.1 Hz, 1H), 7.30 (t, *J* = 7.7 Hz, 1H), 6.96 (d, *J* = 8.0 Hz, 1H), 6.47 (d, *J* = 16.2 Hz, 1H), 4.26 (q, *J* = 7.1 Hz, 2H), 4.13 (q, *J* = 7.1 Hz, 2H), 2.96 (t, *J* = 7.8 Hz, 2H), 2.57 (t, *J* = 7.8 Hz, 2H), 2.24 (d, *J* = 2.4 Hz, 3H), 1.33 (t, *J* = 7.1 Hz, 3H), 1.24 (t, *J* = 7.1 Hz, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 172.6, 167.2, 159.9 (d, *J*_{C-F} = 251.7 Hz), 143.6 (d, *J*_{C-F} = 4.7 Hz), 137.7 (d, *J*_{C-F} = 3.7 Hz), 125.9 (d, *J*_{C-F} = 3.7 Hz), 124.4 (d, *J*_{C-F} = 3.6 Hz), 124.1 (d, *J*_{C-F} = 16.7 Hz), 120.4 (d, *J*_{C-F} = 13.6 Hz), 120.0 (d, *J*_{C-F} = 6.4 Hz), 60.8, 60.7, 34.4, 28.4 (d, *J*_{C-F} = 2.6 Hz), 14.4, 14.3, 10.6 (d, *J*_{C-F} = 7.0 Hz). HRMS (m/z, ESI-TOF): Calcd for C₁₇H₂₁FO₄Na⁺ [M+Na⁺] 331.1316, found 331.1317.



To a solution of ethyl **S5** (0.6 mmol, 1.0 equiv), Pd/C (0.012 mmol, 2 mol %), MeOH (10 mL) under H₂ atmosphere at room temperature stirred for 12 h. Then the crude reaction mixture was extracted with EtOAc and water, The combined organic phase was dried overanhydrous Na₂SO₄ and concentrated under reduced pressure. The residue without further purification.

To a solution of the residue above and LiOH·H₂O (6.0 mmol, 10 equiv) in THF : MeOH : H₂O (6:4:2 mL) at room temperature stirred for 2 h. Then volatile matter was removed under reduced pressure. Then the crude reaction mixture was extracted with EtOAc and water, The combined water phase was added 1N HCl until pH \approx 1, then filtered to give **9c**. (yield: 99%) ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.18 (br, 2H), 7.03 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 7.8 Hz, 1H), 2.79 (td, J = 7.7, 4.5 Hz, 4H), 2.49 – 2.44 (m, 4H), 2.16 (d, J = 2.1 Hz, 3H). ¹³C NMR (101 MHz, DMSO- d_6) δ 173.7, 173.6, 158. 9 (d, $J_{C-F} = 241.1$ Hz), 139.5 (d, $J_{C-F} = 4.0$ Hz), 127.1 (d, $J_{C-F} = 5.8$ Hz), 124.7 (d, $J_{C-F} = 17.6$ Hz), 123. 9 (d, $J_{C-F} = 3.4$ Hz), 122.3 (d, $J_{C-F} = 16.5$ Hz), 34.0, 33.8, 27.4 (d, $J_{C-F} = 2.6$ Hz), 23.8 (d, $J_{C-F} = 3.2$ Hz), 10.2 (d, $J_{C-F} = 6.3$ Hz). HRMS (m/z, ESI-TOF): Calcd for C₁₃H₁₄FO₄⁻ [M-H⁻] 253.0882, found 253.0883.



A suspension of 9c (50.8 mg, 0.20 mmol) in freshly distilled thionyl chloride (3 mL) was gently refluxed to complete solution of the solid (6 h). After evaporation under vacuum the residue was pumped to dryness and without further purification.

To a solution of $S2^2$ (0.6 mmol, 3.0 equiv), triethylamine (1.2 mmol, 6.0 equiv), DCM (10 mL) under N₂ atmosphere at room temperature stirred for 0.5 h. Then S6 was added and stirred for another 12 h. Then the crude reaction mixture was extracted with EtOAc and water, the combined organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting residue was purified by preparative thin layer chromatography using EtOAc/MeOH (20:1-5:1) as the eluent to give the 10c. (yield: 40%) ¹H NMR (400 MHz, DMSO- d_6) δ 8.25 (t, J = 8.9 Hz, 2H), 8.11 (q, J = 6.0 Hz, 2H), 7.30 – 7.12 (m, 10H), 6.84 (t, J = 7.9 Hz, 1H), 6.74 (d, J = 7.8 Hz, 1H), 4.71 (br, 2H), 4.52 – 4.45 (m, 2H), 3.42 – 3.34 (m, 12H), 3.25 – 3.16 (m, 4H), 2.95 (dd, *J* = 13.7, 5.0 Hz, 2H), 2.76 (dd, J = 13.6, 9.6 Hz, 2H), 2.62 (q, J = 7.7 Hz, 4H), 2.36 – 2.23 (m, 4H), 2.09 (d, J = 2.1 Hz, 3H). ¹³C NMR (101 MHz, DMSO- d_6) δ 171.4, 171.2, 171.1, 158.8 (d, $J_{C-F} = 240.7$ Hz), 139.7 (d, $J_{C-F} = 4.0$ Hz), 138.0, 129.3, 129.2, 128.0, 127.0 (d, $J_{C-F} = 5.6$ Hz), 126.3, 125.0, 124.8, 123.8 (d, $J_{C-F} = 3.1$ Hz), 122.1 (d, $J_{C-F} = 3.1$ Hz), 123.8 (d, $J_{C-F} = 3.1$ Hz), 133.8 (d, 16.6 Hz), 72.2, 68.8, 60.2, 54.12, 54.10, 38.0, 37.9, 35.7, 35.3, 28.3, 24.3, 10.2 (d, J_{C-F} = 6.4 Hz). HRMS (m/z, ESI-TOF): Calcd for $C_{39}H_{51}FN_4O_8Na^+$ [M+Na⁺] 745.3583, found 745.3583.

Hydrolysis of 5a:



To a solution of **5a** (0.05 mmol) and LiOH·H₂O (0.5 mmol, 10 equiv) in THF : MeOH : H₂O (1.5:1.0:0.5 mL) at room temperature stirred for 12 h. Then volatile matter was removed under reduced pressure. Then the crude reaction mixture was extracted with EtOAc and water, The combined water phase was added 1N HCl until pH \approx 1, then filtered to give **S7**. ¹H NMR (400 MHz, DMSO-d6) δ 7.75 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 8.1 Hz, 2H), 7.66 – 7.57 (m, 2H), 7.48 (t, J = 7.5 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 6.57 (d, J = 16.0 Hz, 1H). ¹³C NMR (101 MHz, DMSO-d6) δ 169.5, 167.7, 143.6, 142.8, 140.4, 133.2, 132.3, 131.1, 130.4, 129.3, 128.9, 128.1, 127.7, 119.2. HRMS (m/z, ESI-TOF): Calcd for C₁₆H₁₂O₄Na⁺ [M+Na⁺] 291.0628, found 291.0631.

3 NMR Spectrc of Compounds





100 90 f1 (ppm)





S81

































8, 399 8, 390 8, 373 7, 723 7, 723 7, 723 7, 723 7, 723 7, 720 8, 720 7, 720 8, 700 8, 700

















S. 4.11
 S. 4.11
 S. 4.12
 S. 4.12











S. S. 415.
 S. S. 415.
 S. S. 415.
 S. S. 415.
 S. S. 400.
 S. 5. 400.



8, 8, 8, 8, 8, 8, 102
8, 8, 8, 101
8, 8, 8, 101
8, 8, 8, 101
8, 8, 8, 101
9, 101
9, 101
9, 101
9, 101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101
101







8, 8, 335 8, 8, 338

2, 932 2, 916 2, 916 2, 916 2, 894 2, 894 2, 838 2,








2.932 2.912 2.896 2.845 2.811 2.811



8, 427 5, 7, 100 5, 7, 100 6, 97 6, 98 6, 97 6, 98



8,429 8,427 8,427 5,633 7,543 7,543 7,552 7,562 7,752 7,562 7,752 7,562 7,752























S123



-10 90 80 f1 (ppm)













 -10

 8
 398

 8
 398

 8
 339

 9
 3317

 7
 17

 8
 3339

 7
 16

 7
 16

 7
 16

 8
 339

 9
 16

 17
 16

 16
 17

 17
 16

 16
 17

 17
 16

 16
 17

 17
 16

 17
 17

 16
 17

 17
 16

 17
 17

 17
 17

 18
 17

 18
 17

 18
 17

 18
 17

 18
 17

 19
 18

 19
 18

 10
 17

 10
 18

 10
 17

 10
 18

 10



101 196 189	221 221 232 232 232 232 232 232 232 232	881 841 138	245	331 331 366 366 331 331 331	858 841 223
aci aci aci aci	женененененененененененене	မ်းမ်းမ်း	र्च च च	~~~~	444
\sim			\sim		\mathbf{V}







11 104 11 104 11 104 11 104 11 104 11 105 1105 1	212 253 217	890 873 873 849 6694 6694 668 668 668 668 668 106	342 325 307
\$P\$	ਦੇ ਦੇ ਦੇ ਦੇ	લંભંભંભંભંભંભંભંભંભં લં	444
			Y

















401 33896 6657 6657 6657 6657 6657 6657 6657 66	0359 0372 2354 2354 2356 2356 2356	379 362 334 342 346 352 369 365 368 858 858 858 858 858 858 858 852 810	357 340 322 112 112
B B B B B B B B B B B B B B B B B B B	ಪ್ರಪ್ರ ಕ್ರೆಕ್ರೆಕ್	ରି ରି ରି ରି ରି ରି ରା ରା ରା ରା ରା ରା	44444
			Y V











a 3.397 5.357 5.358 5.358 5.358 5.358 5.357 5.357 5.457 5.457 5.457 5.457 5.457 5.456 5.474 5.456 5.474 5.456 5.474 5.4266 5.7444 5.7444 5.7444 5.7444 5.7444 5.7444 5.7444 5.7444 5.744










8.395 8.







8.4.06 8.4.06 8.4.01 8.8.401 8.8.401 8.8.401 8.8.401 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.582 6.803 7.7.525 6.803 7.7.532 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7.7322 6.803 7.7723 7.7326 6.803 7.7723 8.804 7.7723 8.











-10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -120 -130 -140 -150 -160 -170 -180 -190 -2(f1 (ppm)



5,513 5,573 5,573 5,573 5,573 5,135,





-10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 f1 (ppm)





0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -10 -110 -120 -130 -140 -150 -160 -170 -180 -190 -20(f1 (ppm)





0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -110 -110 -120 -130 -140 -150 -160 -170 -180 -190 -201 f1 (ppm)









8 8416 8 8416 8 8416 8 8406 8





0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -2(f1 (ppm)











100 90 f1 (ppm) 0 -1



0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -2¹ f1 (ppm)





0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -20 fl (ppm)





8. 4.15
8. 4.16
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.410
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411
8. 4.411</l





0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -10 -10 -120 -130 -140 -150 -160 -170 -180 -190 -2¹ f1 (ppm)

3.139 3.125 3.125 3.125 3.067 3.087 3.097 3.097 3.0070






-142.818 -142.818 -142.839 -142.897 -156.593 -156.548 -156.548 -156.548 -156.703 -156.548 -152.849 -162.249 -162.249 -162.849 -16







 $\underbrace{ \underbrace{}_{1.365}^{1.403} }_{1.367}$





¹³C NMR (101 MHz, Chloroform-*d*)





0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -2(f1 (ppm)



¹³C NMR (101 MHz, Chloroform-*d*)







¹³C NMR (101 MHz, Chloroform-d)





88.8413 88.8408 88.8408 88.8408 88.8408 84.840 -2.075







0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -2 f1 (ppm)

¹H NMR (400 MHz, Chloroform-*d*) ^{8,8100} ^{8,8100} ^{8,8100} ^{8,8100} ^{8,8100} ^{8,8100} ^{8,8100} ^{1,1280} ^{1,1280}







0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -2 f1 (ppm)

88, 84, 96 88, 84, 96 88, 83, 98 88, 83, 98 86, 87 77, 55





0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -20 f1 (ppm)

 $\underbrace{ \underbrace{}_{1.281}^{1.281} }_{1.245}$



8, 339 8, 337 8, 337 8, 337 8, 337 8, 337 7, 558 8, 337 7, 558 8, 337 7, 558 7, 758 7, 758 7, 558 7, 758 7, 558 7, 758 7, 558 7, 758 7, 558 7, 7587 7, 7587 7, 7587 7, 7587 7, 7587 7, 7587 7, 7587 7, 7587 7







0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 f1 (ppm)





¹³C NMR (101 MHz, Chloroform-*d*)

- 162, 141 - 153, 613 - 149, 1222 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 149, 615 - 153, 617 - 115, 510 - 115





0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 f1 (ppm)









0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -120 -130 -140 -150 -160 -170 -180 -190 f1 (ppm)

8, 338 8,









0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 f1 (ppm)



























100 90 80 70 f1 (ppm) 0 -1

¹H NMR (400 MHz, DMSO-d₆) - 12.179 L 7.048 7.029 7.009 6.927 6.908 соон ноос 9c 2.08 13.5 13.0 12.5 12.0 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 ¹³C NMR (101 MHz, DMSO-*d*₆) < 173.738
173.608</pre> < 139.528</p>< 139.488</p> 127.154 127.096 124.744 124.569 123.895 123.895 123.861 123.861 122.386 $< \frac{10.232}{10.169}$ соон HOOC 9c 100 90 80 f1 (ppm) 190 180 110 70 50 40 30 20 0 -1 170 160 150 140 130 120 60 10




4 References

(1) Yamamoto, T.; Murakami, R.; Suginome. M. Single-Handed Helical Poly(quinoxaline-2,3-diyl)s Bearing Achiral 4-Aminopyrid-3-yl Pendants as Highly Enantioselective, Reusable Chiral Nucleophilic Organocatalysts in the Steglich Reaction. J. Am. Chem. Soc. 2017, 139, 2557–2560.

(2) Liu, J.; Yuan, F.; Ma, X.; Auphedeous, D. Y.; Zhao, C.; Liu, C.; Shen, C.; Feng, C-L. The Cooperative Effect of both Molecular and Supramolecular Chirality on Cell Adhesion. *Angew. Chem., Int. Ed.* **2018**, *57*, 6475.